Research in Your Backyard
Developing Cures, Creating Jobs

PHARMACEUTICAL
CLINICAL TRIALS IN
TEXAS

Dots show locations of clinical trials in the state.
Executive Summary

Clinical Trials in Texas

- Biopharmaceutical research companies are conducting or have conducted more than 8,200 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals (1999 to present).

- Of the more than 8,200 clinical trials, more than 4,300 target the nation’s six most debilitating chronic diseases—asthma, cancer, diabetes, heart disease, mental illnesses and stroke.

Economic Benefits of Clinical Trials in Texas

- Biopharmaceutical research companies have been an important source of jobs, tax revenue and research spending in Texas.

- The 2012 Texas Biotechnology Industry Report from the Office of Governor Rick Perry found that about 125 biopharmaceutical companies have created a large pharmaceutical manufacturing workforce, employing more than 9,500 in Texas, making it one of the top 10 states in the nation for pharmaceutical manufacturing jobs.

- In 2010, the total value of Texas pharmaceutical shipments exceeded $4.7 billion, with manufacturers making total capital investments of nearly $100 million, according to the U.S. Census Bureau.

- Texas is also a leading pharmaceutical research state. In 2012, Texas was ranked second nationally for the number of all clinical trials, with more than 14,000 studies underway, according to the National Institutes of Health database www.clinicaltrials.gov.

- Since 2005, the Texas Emerging Technology Fund (TETF) has invested over $130 million in pharmaceutical-related startups. Funded companies have developed a wide range of technologies, including treatments for cancer, liver disease and obesity.

- Public investment in research and development (R&D) is supported by the state’s vast network of public universities and health-related institutions. In 2010, Texas public institutions of higher education

Freedom fuels innovation, and through our proud tradition of bold thinking and personal freedom, Texas is a natural fit for industries looking to create cutting-edge treatments, develop cures and improve lives. I’m proud of Texas’ ranking in clinical studies, and believe our state has the workforce, talent, universities and business climate to become a national leader for biotech research, development and commercialization.

—Governor Rick Perry
invested more than $2.5 billion on medical and life sciences research, accounting for 61 percent of all higher education R&D expenditures in the state.

- The private sector also has invested in R&D in Texas with 850 private scientific R&D companies employing more than 21,300 workers.
- In addition to R&D facilities, Texas has more than 2,000 medical and testing laboratories, which include blood, pathology, imaging, diagnostics and device testing facilities, employing more than 32,200 workers.
- Company employees in Texas include life sciences researchers, management executives, office and administrative support workers, production workers, engineers, architects, computer and math experts and sales representatives.

About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.

**Clinical Trials in Texas since 1999—Completed and Active**

<table>
<thead>
<tr>
<th>All Clinical Trials</th>
<th>Six Major Chronic Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>8,254</td>
<td>4,390</td>
</tr>
</tbody>
</table>

Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed 10/8/2012.

---

“The clinical trials of new medicines conducted by companies in Texas have been an especially important development for chronic disease patients in the state and all over the country—nearly 4,400 of the trials pursued by biopharmaceutical firms in the Lone Star State have been aimed at cancer, diabetes, heart disease, stroke, mental illnesses and asthma, the nation’s six most debilitating chronic conditions, which have wreaked havoc in Texas. Cancer alone will kill nearly 37,000 Texans this year and about 10 percent of the state’s adults—1.8 million people—are diabetics.”

—Thomas R. Kowalski, President, Texas Healthcare & Bioscience Institute

“In a nutshell, clinical trials of new drugs have been beneficial to patients, the state’s economy and the advance of science. The trials account for 45 to 75 percent of the average $1.2 billion cost of developing one new drug and biopharmaceutical companies generally hire local institutions to do this challenging clinical research work. What’s more, it is significant, and certainly exciting, that a respectable number of drugs tested in Texas over the last 13 years have been new-generation biotechnology treatments, which have the strong potential to be more effective medicines and some of them could improve our ability to predict and even prevent disease.”

—Bill Hammond, President and Chief Executive Officer, Texas Association of Business
• For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.

• Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways

### Clinical Trials in Texas Communities

<table>
<thead>
<tr>
<th>Location</th>
<th>Asthma</th>
<th>Cancer</th>
<th>Diabetes</th>
<th>Heart Disease</th>
<th>Mental Illness</th>
<th>Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amarillo</td>
<td>—</td>
<td>13</td>
<td>1</td>
<td>6</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Austin</td>
<td>4</td>
<td>31</td>
<td>22</td>
<td>12</td>
<td>47</td>
<td>4</td>
</tr>
<tr>
<td>Corpus Christi</td>
<td>—</td>
<td>18</td>
<td>7</td>
<td>3</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Dallas</td>
<td>12</td>
<td>164</td>
<td>58</td>
<td>28</td>
<td>46</td>
<td>8</td>
</tr>
<tr>
<td>El Paso</td>
<td>16</td>
<td>13</td>
<td>6</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Fort Worth</td>
<td>4</td>
<td>41</td>
<td>10</td>
<td>8</td>
<td>—</td>
<td>4</td>
</tr>
<tr>
<td>Houston</td>
<td>6</td>
<td>417</td>
<td>48</td>
<td>35</td>
<td>51</td>
<td>12</td>
</tr>
<tr>
<td>Lubbock</td>
<td>—</td>
<td>15</td>
<td>7</td>
<td>1</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>New Braunfels</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Round Rock</td>
<td>1</td>
<td>10</td>
<td>5</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>San Antonio</td>
<td>18</td>
<td>152</td>
<td>58</td>
<td>16</td>
<td>25</td>
<td>3</td>
</tr>
<tr>
<td>Temple</td>
<td>—</td>
<td>14</td>
<td>—</td>
<td>2</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Waco</td>
<td>13</td>
<td>10</td>
<td>1</td>
<td>3</td>
<td>—</td>
<td>2</td>
</tr>
</tbody>
</table>

Source: www.clinicaltrials.gov

Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed 11/29/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. Please note that database results can change on a daily basis.
to make existing approved drugs more effective and easier to use with fewer side effects.

- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.

- Clinical trial progress reports must be submitted at least annually to the FDA and IRB.

- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation’s health and our ability to treat and prevent medical conditions.

- According to the Centers for Disease Control and Prevention, today, in the United States:
  - Patients with chronic diseases account for 75 cents of every dollar spent on health care.
  - Chronic diseases are the leading cause of death and disability.
  - Chronic diseases are a leading driver of rising health care costs with expenses totaling billions of dollars every year.
  - Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout Texas.
  - Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 4,390 clinical trials of potential new medicines in Texas alone for asthma, cancer, heart disease, stroke, diabetes and mental illnesses. Of these trials, 914 are either not yet recruiting or are just now seeking Texas patients.
  - Many of the state’s clinical tests involve collaborations with such respected local institutions as the University of Texas Health Sciences Centers and Texas A&M University School of Medicine.
  - Many of the medicines being clinically tested here are new-generation biotechnology treatments.

<table>
<thead>
<tr>
<th>Chronic Disease</th>
<th>All Clinical Trials</th>
<th>Clinical Trials Still Recruiting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>138</td>
<td>29</td>
</tr>
<tr>
<td>Cancer</td>
<td>2,603</td>
<td>633</td>
</tr>
<tr>
<td>Diabetes</td>
<td>656</td>
<td>92</td>
</tr>
<tr>
<td>Heart Disease</td>
<td>268</td>
<td>49</td>
</tr>
<tr>
<td>Mental Illness</td>
<td>676</td>
<td>96</td>
</tr>
<tr>
<td>Stroke</td>
<td>49</td>
<td>15</td>
</tr>
<tr>
<td>Total</td>
<td>4,390</td>
<td>914</td>
</tr>
</tbody>
</table>

Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed 10/8/2012. Some clinical trials appear in more than one disease category.
Clinical Trials in Texas

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the $1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It’s essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Texas, biopharmaceutical companies are providing funds to have trials conducted at the states’ well-respected university medical schools and science centers, local hospitals and clinical research organizations. According to U.S. News and World Report, the University of Texas Southwestern Medical Center in Dallas ranked 20th, Baylor College of Medicine in Houston ranked 21st, the University of Texas Health Science Center in Houston ranked 55th, the University of Texas Health Science Center in San Antonio ranked 67th, and the Texas A&M Health Science Center in Bryan ranked 83rd among this year’s top 100 research-oriented medical schools in the United States. Other listed medical schools included Texas Tech University Health Sciences Center in Lubbock, the University of North Texas Health Science Center in Fort Worth, and the University of Texas Medical Branch in Galveston.

<table>
<thead>
<tr>
<th>Clinical Trials for Top Chronic Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic Disease</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Cancer</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Heart Disease</td>
</tr>
<tr>
<td>Mental Illness</td>
</tr>
<tr>
<td>Stroke</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

Source: www.clinicaltrials.gov
Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed 10/8/2012. Some clinical trials appear in more than one disease category.
Asthma is a debilitating condition for more than 23 million Americans, including 7 million children under the age of 18. The toll is also severe in Texas where, in 2008, more than 1.2 million adults and nearly 600,000 children in Texas suffered from asthma, according to the U.S. Centers for Disease Control and Prevention (CDC).

Currently, 29 clinical trials of new asthma medicines are recruiting patients in Texas. Trials are being conducted at the Western Sky Medical Research in El Paso, North Texas Institute for Clinical Trials in Fort Worth and Alamo Clinical Research in Austin.

Cancer, the second leading cause of death in the United States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Texas, more than 110,000 new cancer cases will be diagnosed this year and 36,820 victims in the state will die, according to the American Cancer Society.

Currently, 633 clinical trials of new cancer medicines are recruiting patients in Texas. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the Cancer Therapy and Research Center at University of Texas in San Antonio, the Charles A. Sammons Cancer Center at Baylor University in Dallas, M.D. Anderson Cancer Center at the University of Texas in Houston, and the Texas Tech University Health Science Center in El Paso.

Diabetes affects more than 20 million Americans—about 8 percent of the U.S. population—and nearly one-third are unaware they have the disease. In Texas, about 10 percent of adults—1.8 million people—have been afflicted with diabetes, according to the Texas Department of State Health Services. In 2010, diabetes was the cause of death of 4,738 residents.

Currently, 92 diabetes clinical tests are seeking patients in Texas. The trials are being conducted in Dallas at the Baylor Research Institute, Dallas South Hampton Community Hospital, and the University of Texas Southwestern Medical Center, and the Texas Center for Drug Development and Methodist Hospital in Houston.

Heart disease and stroke are the first and third leading disease causes of death in the United States and the first and fourth in Texas. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Texas, in 2010, more than 38,000 residents died from some form of heart disease and 9,154 died from a stroke, according to the Texas Department of State Health Services.

Currently, 49 heart disease and 15 stroke clinical tests are seeking patients in Texas. The trials are underway at the Jack and Jane Hamilton Heart and Vascular Hospital at Baylor in Dallas, the DeBakey Heart and Vascular Center at Methodist Hospital in Houston, the San Antonio Endovascular and Heart Institute in San Antonio, the Cardiology Center of Amarillo, and the Heart Hospital of Austin in Austin.

Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Texas, about 833,000 adults live with serious mental illness and about 288,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 96 clinical trials for mental illness are recruiting patients in Texas. The trials are taking place at the Baylor College of Medicine in Houston, Red Oak Psychiatry Associates in Houston, San Antonio Psychiatric Research Center in San Antonio, Senior Adults Specialty Research in Austin, and the University of Texas in Houston, San Antonio and Dallas.

Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored by the National Institutes of Health. Information on medicines in development is also available on www.phrma.org, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA), under “Clinical Research and Trials.”
Many of the medicines being tested in Texas are cutting-edge biotechnology drugs.

America’s biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Texas is one of the states where new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict it and eventually prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at Texas medical schools and research centers feature these technologies. For example:

- A genetically-modified virus-based vaccine to treat melanoma.
- A monoclonal antibody for the treatment of cancer.
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation’s biopharmaceutical companies and Texas research institutions are working together to attack disease. The biotechnology medicines and vaccines in development are helping to expand the frontiers of science and potentially bring more and better treatments to patients.
Conclusion

Biopharmaceutical companies’ close collaboration with clinicians and research institutions in Texas benefits patients, the state’s economy and the advancement of science and patient care. Clinical trials provide stimulating biopharmaceutical research work and a reliable source of revenue for the state’s university medical schools and science centers, hospitals and clinical organizations and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What’s more, Texans considering participation in clinical trials of new drugs have a wide range of choices, including 914 tests of new medicines for the six most debilitating chronic diseases in America.
The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world. It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

<table>
<thead>
<tr>
<th>Discovery/ Preclinical Testing</th>
<th>Clinical Trials</th>
<th>FDA</th>
<th>Phase IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years</td>
<td>Phase I</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Test Population</td>
<td>Phase II</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Laboratory and animal studies</td>
<td>Phase III</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td>Purpose</td>
<td>FDA</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Assess safety, biological activity and formulations</td>
<td>File IND at FDA</td>
<td>File NDA/BLA at FDA</td>
<td>Review process/ approval</td>
</tr>
<tr>
<td>Success Rate</td>
<td>5,000 compounds evaluated</td>
<td>5 enter trials</td>
<td>1 approved</td>
</tr>
</tbody>
</table>

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world. It takes 10-15 years on average, for an experimental drug to travel from the lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are usually developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, determine a safe dosage range, and identify potential side effects.

Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and further evaluate its short-term safety.

Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 patients (but sometimes many more thousands), to generate statistically significant evidence to confirm its safety and effectiveness. They are the longest studies, and usually take place in multiple sites around the world.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated $49.5 billion in research and development in 2011.
The Good News—Many Clinical Trials are Still Recruiting

There are 914 clinical trials of new chronic disease drugs recruiting patients in Texas. These trials target the six most debilitating chronic conditions—cancer, heart disease, stroke, asthma, diabetes and mental illnesses.

### Clinical Trials in Texas Communities

<table>
<thead>
<tr>
<th>Location</th>
<th>Asthma</th>
<th>Cancer</th>
<th>Diabetes</th>
<th>Heart Disease</th>
<th>Mental Illness</th>
<th>Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amarillo</td>
<td>—</td>
<td>13</td>
<td>1</td>
<td>6</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Austin</td>
<td>4</td>
<td>31</td>
<td>22</td>
<td>12</td>
<td>47</td>
<td>4</td>
</tr>
<tr>
<td>Corpus Christi</td>
<td>—</td>
<td>18</td>
<td>7</td>
<td>3</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Dallas</td>
<td>12</td>
<td>164</td>
<td>58</td>
<td>28</td>
<td>46</td>
<td>8</td>
</tr>
<tr>
<td>El Paso</td>
<td>16</td>
<td>13</td>
<td>6</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Fort Worth</td>
<td>4</td>
<td>41</td>
<td>10</td>
<td>8</td>
<td>—</td>
<td>4</td>
</tr>
<tr>
<td>Houston</td>
<td>6</td>
<td>417</td>
<td>48</td>
<td>35</td>
<td>51</td>
<td>12</td>
</tr>
<tr>
<td>Lubbock</td>
<td>—</td>
<td>15</td>
<td>7</td>
<td>1</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>New Braunfels</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Round Rock</td>
<td>1</td>
<td>10</td>
<td>5</td>
<td>1</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>San Antonio</td>
<td>18</td>
<td>152</td>
<td>58</td>
<td>16</td>
<td>25</td>
<td>3</td>
</tr>
<tr>
<td>Temple</td>
<td>—</td>
<td>14</td>
<td>—</td>
<td>2</td>
<td>—</td>
<td>1</td>
</tr>
<tr>
<td>Waco</td>
<td>13</td>
<td>10</td>
<td>1</td>
<td>3</td>
<td>—</td>
<td>2</td>
</tr>
</tbody>
</table>

Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Note: Search criteria = Texas, Phase I, II, III; industry only. Search performed 11/29/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city. Please note that database results can change on a daily basis.
The Good News—Many Clinical Trials are Still Recruiting
(continued)

Asthma—Leading Institutions Conducting Clinical Trials
Alamo Clinical Research Associates, San Antonio
Allergy & Asthma Care of Waco, Waco
Allergy & Asthma Center of Boerne, Boerne
Allergy / Immunology Research Center of North Texas, Dallas
Allergy Asthma Research Institute, Waco
Breath of Life Research Institute, Katy
Central Texas Health Research, New Braunfels
Dallas Allergy Immunology Research, Dallas
Gastroenterology Consultants, Houston
Isis Clinical Research, Austin
Live Oak Allergy and Asthma Clinic, Live Oak
North Texas Institute for Clinical Trials, Fort Worth
Pharmaceutical Research & Consulting, Dallas
Pioneer Research Solutions, Houston
Quality Assurance Research Center, San Antonio
SAM Clinical Research Center, San Antonio
Sirius Clinical Research, Austin
Southwest Allergy and Asthma Research Center, San Antonio
Sylvana Research Associates, San Antonio
Tekton Research, Austin
TTS Research, Boerne
Western Sky Medical Research, El Paso

Cancer—Leading Institutions Conducting Clinical Trials
Advanced Research Network, Houston, Lubbock
Baylor College of Medicine, Houston
Baylor Research Institute, Dallas
Ben Taub Hospital, Houston
Brooke Army Medical Center, Fort Sam Houston
Cancer Care Centers of South Texas, San Antonio
Cancer Center of the High Plains, Amarillo
Cancer Therapy and Research Center at University of Texas, San Antonio
Central Austin Cancer Center, Austin
Central Texas Veterans Healthcare System, Temple
Charles A. Sammons Cancer Center at Baylor University, Dallas
Dallas Presbyterian Hospital, Dallas
Don & Sybil Harrington Cancer Center, Amarillo
East Texas Hematology Clinic, Lufkin
El Paso Cancer Treatment Center-East, El Paso
Excel Diagnostics Imaging Clinic, Houston
Harry Hines Medical Center, Dallas
Joe Arrington Cancer Research and Treatment Center, Lubbock
M.D. Anderson Cancer Center at the University of Texas, Houston
Marnie McFaddin Ward Cancer Center, Beaumont
Mary Crowley Cancer Research Center, Dallas
Midland Allison Cancer Center, Midland
Oncology Consultants, Houston
Scott and White Memorial Hospital, Temple
South Texas Accelerated Research Therapeutics, San Antonio
South Texas Comprehensive Cancer Centers, Corpus Christi
South Texas Oncology and Hematology, San Antonio
Southwest Cancer Treatment and Research Center, Lubbock
St. Luke’s Episcopal Hospital, Houston
Texas Cancer Center at Medical City, Dallas
Texas Oncology Cancer Care and Research Center, Waco
Texas Oncology, Abilene
Texas Oncology, Amarillo
Texas Oncology, Austin
Texas Oncology, Bedford
Texas Oncology, Dallas
Texas Oncology, Denton
Texas Oncology, El Paso
Texas Oncology, Fort Worth
Texas Oncology, Garland
Texas Oncology, Grapevine
Texas Oncology, Lewisville
Texas Oncology, McAllen
Texas Oncology, Paris
Texas Oncology, Plano
Texas Oncology, Round Rock
Texas Oncology, Sherman
Texas Oncology, Tyler
Texas Oncology, Waco
Texas Oncology—Medical City, Dallas
Texas Oncology—Memorial City, Houston
Texas Tech University Health Science Center, El Paso
Texas Urology Specialists, Tomball
The Methodist Hospital, Houston
Tyler Cancer Center, Tyler
University of Texas Health Science Center Institute for Drug Development, San Antonio
University of Texas Health Sciences, San Antonio
University of Texas Medical Branch, Galveston
University of Texas Southwestern Medical Center, Dallas
Urology Associates of North Texas, Arlington
Urology Associates of South Texas, McAllen
Urology Clinics of North Texas, Dallas

Arlington Family Research Center, Arlington
Austin Retina Associates, Austin
Baylor Endocrine Center, Dallas
Baylor Eye Physicians and Surgeons, Houston
Baylor Research Institute, Dallas
Breco Research, Sugarland
Centex Research, Houston
Cetero Research, San Antonio
Complete Family Foot Care, McAllen
Covenant Clinical Research, San Antonio
Dallas Diabetes and Endocrine Research Center, Dallas
Dependable Clinical Research, Houston
Diabetech, Dallas
DiscoveResearch, Beaumont
Endeavor Clinical Trials, San Antonio
Excel Clinical Research, Houston
Heart Care Center of Northwest Houston, Houston
Hill Country Medical Associates, New Braunfels
Hillcrest Family Health Center, Waco
Houston Neurocare, Houston
Humble Cardiology Associates, Humble
Innovative Clinical Trials, San Antonio
Internal Medicine Clinical Research, Dallas
Juno Research, Houston
Junoi Sun Research Institute, San Antonio
KRK Medical Research, Dallas
Lone Star Clinical Research, Houston
Lone Star Heart Center, Amarillo
Med-Olam Clinical Research, Pasadena
Mercury Clinical Research, Houston
Methodist Neurological Institute, Houston
Millennium Research, Houston
Mountain Diabetes & Endocrine Center, Dallas
North Hills Medical Research, North Richland Hills
Northeast Clinical Research of San Antonio, San Antonio

Diabetes—Leading Institutions Conducting Clinical Trials
3rd Coast Research Associates, Corpus Christi
Abbott Clinical Research Group, San Antonio
Advances in Health, Houston

Research in Your Backyard: Developing Cures, Creating Jobs
Northwest Houston Heart Center, Houston
Padre Coast Medical Associates, Corpus Christi
Paragon Research Center, San Antonio
Podiatry Associates, San Antonio
Protenium Clinical Research, Hurst
R/D Clinical Research, Lake Jackson
Radiant Research, Dallas
Renaissance Clinical Research and Hypertension, Dallas
Renal Associates, San Antonio
Research Across America, Houston
Research Institute of Dallas, Dallas
Retina and Vitreous of Texas, Houston
Retina Research Center, Austin
Retinal Consultants of Houston, Houston
Retinal Consultants of San Antonio, San Antonio
San Antonio Kidney Disease Center Physicians Group, San Antonio
Seton Heart Institute, Austin
Sonterra Clinical Research, San Antonio
South Hampton Community Hospital, Dallas
Southwest Clinical Trials, Houston
Southwest Houston Research, Houston
T&R Clinic, Fort Worth
Tarrant Nephrology Associates, Fort Worth
Texas Center for Drug Development, Houston
Texas Diabetes and Endocrinology, Austin
Texas Diabetes and Endocrinology, Round Rock
Texas Diabetes, Austin, El Paso
Texas Retina Associates, Dallas
Texas Retina Associates, Lubbock
The Methodist Hospital, Houston
University of Texas Health Science Center, Houston
University of Texas Southwestern Medical Center, Dallas
Valley Retina Associates, McAllen
Village Family Practice, Houston
West Houston Clinical Research, Houston

Heart Disease—Leading Institutions Conducting Clinical Trials
3rd Coast Research Associates, Corpus Christi
Advances in Health, Houston
Baylor Heart and Vascular Hospital, Dallas
Baylor Research Institute, Plano
Baylor University Medical Center, Dallas
Cardiology Associates of Corpus Christi, Corpus Christi
Cardiovascular Associates of East Texas, Tyler
Cardiology Center of Amarillo, Amarillo
Clinical Trial Network, Houston
Dallas VA Medical Center, Dallas
DiscoveResearch, Beaumont
East Texas Cardiology, Houston
Gamma Medical Research, Mission
Heart Hospital of Austin, Austin
Hillcrest Family Health Center, Waco
Humble Cardiology Associates, Humble
Jack and Jane Hamilton Heart and Vascular Hospital at Baylor, Dallas
Katy Cardiology Associates, Katy
Leachman Cardiology, Houston
Lone Star Heart Center, Amarillo
Medical City Dallas, Dallas
Memorial Hermann, Houston
Methodist DeBakey Heart and Vascular Center at Methodist Hospital, Houston
Methodist Health Systems, San Antonio
NECRSA, Schertz
North Dallas Research Associates, McKinney
North Texas Healthcare System, Department of Veteran’s Affairs, Dallas
Northwest Houston Heart Center, Tomball
Padre Coast Medical Associates, Corpus Christi
Protenium Clinical Research, Hurst
R/D Clinical Research, Lake Jackson
Radiant Research, Dallas
Radiant Research, San Antonio
Research Institute of Dallas, Dallas
San Antonio Endovascular and Heart Institute, San Antonio
Scott & White Memorial Hospital, Temple
Sonterra Clinical Research, San Antonio
South Texas Cardiovascular Consultants, San Antonio
Texas Cardiac Arrhythmia Research Foundation, Austin
Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston
The Cardiology Center of Amarillo, Amarillo
The Heart Center of Northwest Houston, Houston
The Heart Hospital Baylor, Plano
The Medical Center of Plano, Plano
Tyler Cardiovascular Consultants, Tyler
University Medical Center at Brackenridge, Austin
University of Texas Health Science Center, Houston
University of Texas Health Science Center, San Antonio
University of Texas Medical Branch, Galveston
University of Texas Southwestern Medical Center, Dallas
Veterans Affairs North Texas Health Care Systems, Dallas
Victoria Heart and Vascular Center, Victoria
West Houston Area Clinical Trial Consultants, Houston

Mental Illness—Leading Institutions Conducting Clinical Trials
Bay Area Clinical Services, Friendswood
Baylor College of Medicine, Houston
Bayou City Research, Houston
Ben Taub General Hospital, Houston
CEDRA Clinical Research, San Antonio
Claghorn-Lesem Research Clinic, Houston
Clinical Trials of Texas, San Antonio
Community Clinical Research, Austin
Family Psychiatry of the Woodlands, The Woodlands
Future Search Trials of Dallas, Dallas
FutureSearch Clinical Trials, Austin
Grayline Clinical Drug Trials, Wichita Falls
Harry Croft and Associates, San Antonio

Houston Clinical Trials, Houston
Houston Sleep Center, Houston
InSite Clinical Research, DeSoto
Integra Clinical Research, San Antonio
KRK Medical Research, Dallas
Michael E. DeBakey VA Medical Center, Houston
Paragon Research Center, San Antonio
Pillar Clinical Research, Dallas
R/D Clinical Research, Lake Jackson
Red Oak Psychiatry Associates, Houston
Research Across America, Dallas
San Antonio Psychiatric Research Center, San Antonio
Senior Adults Specialty Research, Austin
Sleep Medicine Associates of Texas, Dallas
South Texas Veterans Health Care System, San Antonio
Texas Neurology, Dallas
University Hills Clinical Research, Irving
University of Texas Health Sciences Center, Houston
University of Texas Health Sciences Center, San Antonio
University of Texas Southwestern Medical Center, Dallas
Westex Clinical Investigations, Lubbock
Wharton Research Center, Wharton

Stroke—Leading Institutions Conducting Clinical Trials
Baylor Research Institute, Dallas
Dallas Veterans Administration Medical Center, Dallas
Heart Hospital of Austin, Austin
Methodist Neurological Institute, Houston
Presbyterian Hospital of Dallas, Dallas
St. Luke’s Episcopal Hospital, Houston
The Methodist Hospital, Houston
University Medical Center at Brackenridge, Austin
University of Texas Medical Branch, Galveston
University of Texas Medical School, Houston
University of Texas Southwestern Medical Center, Dallas
The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto www.clinicaltrials.gov, the clinical tests database of the National Institutes of Health.

### Asthma

(29 clinical trials recruiting)

| Study 1: | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids  
http://ClinicalTrials.gov/show/NCT01479621 |
|---|---|
| Study 2: | A 12-week Study to Compare the Efficacy and Safety of Albuterol in Dry Powder Inhaler Versus a Placebo in People 12 Years and Older With Persistent Asthma  
http://ClinicalTrials.gov/show/NCT01424813 |
| Study 3: | A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications  
http://ClinicalTrials.gov/show/NCT01576718 |
| Study 4: | Efficacy and Safety Study to Compare Formoterol Fumurate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma  
http://ClinicalTrials.gov/show/NCT01641081 |
| Study 5: | A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma  
http://ClinicalTrials.gov/show/NCT01285323 |
| Study 6: | A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma  
http://ClinicalTrials.gov/show/NCT00809757 |
| Study 7: | A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma  
http://ClinicalTrials.gov/show/NCT01287039 |
<table>
<thead>
<tr>
<th>Study 8:</th>
<th>Study 16:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose Finding Study for QAW039 in Asthma</td>
<td>A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01437735">http://ClinicalTrials.gov/show/NCT01437735</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01582503">http://ClinicalTrials.gov/show/NCT01582503</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 9:</th>
<th>Study 17:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)</td>
<td>Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01502371">http://ClinicalTrials.gov/show/NCT01502371</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01508936">http://ClinicalTrials.gov/show/NCT01508936</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 10:</th>
<th>Study 18:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A 6-week Study in Asthmatic Children Aged 6 to &lt;12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo</td>
<td>A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01136382">http://ClinicalTrials.gov/show/NCT01136382</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01270464">http://ClinicalTrials.gov/show/NCT01270464</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 11:</th>
<th>Study 19:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma</td>
<td>Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01591044">http://ClinicalTrials.gov/show/NCT01591044</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01581177">http://ClinicalTrials.gov/show/NCT01581177</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 12:</th>
<th>Study 20:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma</td>
<td>Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01436110">http://ClinicalTrials.gov/show/NCT01436110</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01634139">http://ClinicalTrials.gov/show/NCT01634139</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 13:</th>
<th>Study 21:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012 AM1)</td>
<td>Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01656395">http://ClinicalTrials.gov/show/NCT01656395</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01257230">http://ClinicalTrials.gov/show/NCT01257230</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 14:</th>
<th>Study 22:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)</td>
<td>A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01545440">http://ClinicalTrials.gov/show/NCT01545440</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01641692">http://ClinicalTrials.gov/show/NCT01641692</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 15:</th>
<th>Study 23:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)</td>
<td>A Study of ARRY-502 in Patients With Persistent Asthma</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01545453">http://ClinicalTrials.gov/show/NCT01545453</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01561690">http://ClinicalTrials.gov/show/NCT01561690</a></td>
</tr>
<tr>
<td>Study 24:</td>
<td>Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01573767">http://ClinicalTrials.gov/show/NCT01573767</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 25:</th>
<th>Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00642616">http://ClinicalTrials.gov/show/NCT00642616</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 26:</th>
<th>A Dose-ranging Study of Fluticasone Furoate (FF)</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01563029">http://ClinicalTrials.gov/show/NCT01563029</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 27:</th>
<th>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01008410">http://ClinicalTrials.gov/show/NCT01008410</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 28:</th>
<th>Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01008423">http://ClinicalTrials.gov/show/NCT01008423</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 29:</th>
<th>The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01349673">http://ClinicalTrials.gov/show/NCT01349673</a></td>
<td></td>
</tr>
</tbody>
</table>

**Cancer**

(633 clinical trials recruiting)

<table>
<thead>
<tr>
<th>Study 1:</th>
<th>A Study of LY2228820 for Recurrent Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01663857">http://ClinicalTrials.gov/show/NCT01663857</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 2:</th>
<th>A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00975767">http://ClinicalTrials.gov/show/NCT00975767</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 3:</th>
<th>Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01495247">http://ClinicalTrials.gov/show/NCT01495247</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 4:</th>
<th>A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01421472">http://ClinicalTrials.gov/show/NCT01421472</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 5:</th>
<th>Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01279291">http://ClinicalTrials.gov/show/NCT01279291</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 6:</th>
<th>TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01204749">http://ClinicalTrials.gov/show/NCT01204749</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 7:</th>
<th>TRINOVA-3: A Study of AMG 386 or Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01493505">http://ClinicalTrials.gov/show/NCT01493505</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 8:</th>
<th>Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00858364">http://ClinicalTrials.gov/show/NCT00858364</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 9:</th>
<th>Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01605227">http://ClinicalTrials.gov/show/NCT01605227</a></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 10:</th>
<th>A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01529112">http://ClinicalTrials.gov/show/NCT01529112</a></td>
<td></td>
</tr>
</tbody>
</table>
| Study 11: | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors  
http://ClinicalTrials.gov/show/NCT01576666 |
|---|---|
| Study 12: | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer  
http://ClinicalTrials.gov/show/NCT01379534 |
| Study 13: | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin’s Lymphoma or Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01353625 |
| Study 14: | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer  
http://ClinicalTrials.gov/show/NCT01522443 |
| Study 15: | A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours  
http://ClinicalTrials.gov/show/NCT01578239 |
| Study 16: | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer  
http://ClinicalTrials.gov/show/NCT01188187 |
| Study 17: | A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy  
http://ClinicalTrials.gov/show/NCT01168973 |
| Study 18: | PAVES: Pegfilgrastim Anti-VEGF Evaluation Study  
http://ClinicalTrials.gov/show/NCT00911170 |
| Study 19: | Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer  
http://ClinicalTrials.gov/show/NCT01217697 |
| Study 20: | A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy  
http://ClinicalTrials.gov/show/NCT00925600 |
| Study 21: | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)  
http://ClinicalTrials.gov/show/NCT01077154 |
| Study 22: | Study of PX-866 and Docetaxel in Solid Tumors  
http://ClinicalTrials.gov/show/NCT01204099 |
| Study 23: | Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer  
http://ClinicalTrials.gov/show/NCT01664923 |
| Study 24: | The BEACON Study (Breast Cancer Outcomes With NKTR-102)  
http://ClinicalTrials.gov/show/NCT01492101 |
| Study 25: | Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer  
http://ClinicalTrials.gov/show/NCT01082068 |
| Study 26: | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone  
http://ClinicalTrials.gov/show/NCT00968968 |
Study 27:
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
http://ClinicalTrials.gov/show/NCT01200992

Study 28:
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
http://ClinicalTrials.gov/show/NCT01456325

Study 29:
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
http://ClinicalTrials.gov/show/NCT01590719

Study 30:
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
http://ClinicalTrials.gov/show/NCT01358877

Study 31:
Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
http://ClinicalTrials.gov/show/NCT00320710

Study 32:
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
http://ClinicalTrials.gov/show/NCT01322490

Study 33:
Phase 1–2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
http://ClinicalTrials.gov/show/NCT01416038

Study 34:
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Postmenopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
http://ClinicalTrials.gov/show/NCT00696072

Study 35:
MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
http://ClinicalTrials.gov/show/NCT01091428

Study 36:
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
http://ClinicalTrials.gov/show/NCT01045421

Study 37:
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
http://ClinicalTrials.gov/show/NCT00531284

Study 38:
EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01360840

Study 39:
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
http://ClinicalTrials.gov/show/NCT01284192

Study 40:
Safety, PK of AKT and MEK Combination
http://ClinicalTrials.gov/show/NCT01138085

Study 41:
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
http://ClinicalTrials.gov/show/NCT01517802
**Study 42:**
Immunotherapy Study for Surgically Resected Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01072981

**Study 43:**
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01309126

**Study 44:**
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
http://ClinicalTrials.gov/show/NCT01436968

**Study 45:**
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
http://ClinicalTrials.gov/show/NCT01088529

**Study 46:**
A Study in Second Line Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01183780

**Study 47:**
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
http://ClinicalTrials.gov/show/NCT01170650

**Study 48:**
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
http://ClinicalTrials.gov/show/NCT01166490

**Study 49:**
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
http://ClinicalTrials.gov/show/NCT01617668

**Study 50:**
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01177397

**Study 51:**
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01268059

**Study 52:**
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT00840749

**Study 53:**
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
http://ClinicalTrials.gov/show/NCT00908024

**Study 54:**
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01362400

**Study 55:**
Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
http://ClinicalTrials.gov/show/NCT01337089

**Study 56:**
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
http://ClinicalTrials.gov/show/NCT01269346

**Study 57:**
Efficacy and Safety Study of NeuVax™ Vaccine to Prevent Breast Cancer Recurrence
http://ClinicalTrials.gov/show/NCT01479244
Study 58:
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01685138

Study 59:
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane
http://ClinicalTrials.gov/show/NCT01461915

Study 60:
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
http://ClinicalTrials.gov/show/NCT01528345

Study 61:
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
http://ClinicalTrials.gov/show/NCT01427933

Study 62:
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
http://ClinicalTrials.gov/show/NCT01572727

Study 63:
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
http://ClinicalTrials.gov/show/NCT01610284

Study 64:
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
http://ClinicalTrials.gov/show/NCT01454089

Study 65:
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01446159

Study 66:
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
http://ClinicalTrials.gov/show/NCT01234402

Study 67:
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
http://ClinicalTrials.gov/show/NCT01381874

Study 68:
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
http://ClinicalTrials.gov/show/NCT01285557

Study 69:
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
http://ClinicalTrials.gov/show/NCT01505530

Study 70:
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
http://ClinicalTrials.gov/show/NCT01633060

Study 71:
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01193257

Study 72:
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01234311
Study 73:
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01374425

Study 74:
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
http://ClinicalTrials.gov/show/NCT01419222

Study 75:
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01297491

Study 76:
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
http://ClinicalTrials.gov/show/NCT01555710

Study 77:
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
http://ClinicalTrials.gov/show/NCT00874107

Study 78:
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01663727

Study 79:
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01237678

Study 80:
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
http://ClinicalTrials.gov/show/NCT00927589

Study 81:
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
http://ClinicalTrials.gov/show/NCT01437566

Study 82:
Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
http://ClinicalTrials.gov/show/NCT01642004

Study 83:
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM5)
http://ClinicalTrials.gov/show/NCT01295827

Study 84:
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)
http://ClinicalTrials.gov/show/NCT01419197

Study 85:
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer
http://ClinicalTrials.gov/show/NCT01491737

Study 86:
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
http://ClinicalTrials.gov/show/NCT01562626
<table>
<thead>
<tr>
<th>Study 87:</th>
<th>Study 88:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and Efficacy Trial of Iplimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer</td>
<td>A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01471197">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01460134">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 89:</th>
<th>Study 90:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of IMC-TR1 in Patients With Advanced Solid Tumors</td>
<td>Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01646203">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00896454">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 91:</th>
<th>Study 92:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer</td>
<td>A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01598077">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01059643">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 93:</th>
<th>Study 94:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety Study of PLX108-01 in Patients With Solid Tumors</td>
<td>Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01004861">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01505153">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 95:</th>
<th>Study 96:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase 1b/2 Study of OMP-59R5 in Combination With Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer</td>
<td>A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01647828">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01154140">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 97:</th>
<th>Study 98:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer</td>
<td>A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01220128">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01510561">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 99:</th>
<th>Study 100:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-escalation Study of Oral CX-4945</td>
<td>A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00891280">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01650194">Link</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 101:</th>
<th>Study 102:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer</td>
<td>A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01234337">Link</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00813384">Link</a></td>
</tr>
</tbody>
</table>
Study 103:
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
http://ClinicalTrials.gov/show/NCT01219699

Study 104:
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
http://ClinicalTrials.gov/show/NCT01471847

Study 105:
Study of a Drug [DCVax*-L] to Treat Newly Diagnosed GBM Brain Cancer
http://ClinicalTrials.gov/show/NCT00045968

Study 106:
A Study of AMG 337 in Subjects With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01253707

Study 107:
A Study of AMG 820 in Subjects With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01444404

Study 108:
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
http://ClinicalTrials.gov/show/NCT01628913

Study 109:
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
http://ClinicalTrials.gov/show/NCT01351103

Study 110:
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01466569

Study 111:
LDK738 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
http://ClinicalTrials.gov/show/NCT01685060

Study 112:
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer
http://ClinicalTrials.gov/show/NCT01363947

Study 113:
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
http://ClinicalTrials.gov/show/NCT01647789

Study 114:
M402 and Gemcitabine in Pancreatic Cancer-Part A
http://ClinicalTrials.gov/show/NCT01621243

Study 115:
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
http://ClinicalTrials.gov/show/NCT01497470

Study 116:
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
http://ClinicalTrials.gov/show/NCT01288911

Study 117:
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
http://ClinicalTrials.gov/show/NCT01480583

Study 118:
A Study in Head and Neck Cancer
http://ClinicalTrials.gov/show/NCT01081041

Study 119:
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
http://ClinicalTrials.gov/show/NCT00979134
<table>
<thead>
<tr>
<th>Study 120:</th>
<th>Study 127:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer</td>
<td>Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01309230">http://ClinicalTrials.gov/show/NCT01309230</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01545947">http://ClinicalTrials.gov/show/NCT01545947</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 121:</th>
<th>Study 128:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer</td>
<td>Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01186991">http://ClinicalTrials.gov/show/NCT01186991</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01514123">http://ClinicalTrials.gov/show/NCT01514123</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 122:</th>
<th>Study 129:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Multi-arm Phase I Safety Study of BMS-936558 in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib or Monotherapy Alone in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)</td>
<td>Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01454102">http://ClinicalTrials.gov/show/NCT01454102</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01700270">http://ClinicalTrials.gov/show/NCT01700270</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 123:</th>
<th>Study 130:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions</td>
<td>Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01017185">http://ClinicalTrials.gov/show/NCT01017185</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01395017">http://ClinicalTrials.gov/show/NCT01395017</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 124:</th>
<th>Study 131:</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPECTT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer</td>
<td>Intravesical Administration of INSTILADRIN (rAd-IFN With Syn3) in Patients With Bladder Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01001377">http://ClinicalTrials.gov/show/NCT01001377</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01687244">http://ClinicalTrials.gov/show/NCT01687244</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 125:</th>
<th>Study 132:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer</td>
<td>Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01620515">http://ClinicalTrials.gov/show/NCT01620515</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01415960">http://ClinicalTrials.gov/show/NCT01415960</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 126:</th>
<th>Study 133:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies</td>
<td>Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01461538">http://ClinicalTrials.gov/show/NCT01461538</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01361607">http://ClinicalTrials.gov/show/NCT01361607</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 127:</th>
<th>Study 134:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer</td>
<td>A Phase 1 Study in Patients With Advanced Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01545947">http://ClinicalTrials.gov/show/NCT01545947</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01115790">http://ClinicalTrials.gov/show/NCT01115790</a></td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Study 135:</strong></td>
<td>The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer <a href="http://ClinicalTrials.gov/show/NCT01506609">http://ClinicalTrials.gov/show/NCT01506609</a></td>
</tr>
<tr>
<td><strong>Study 136:</strong></td>
<td>Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients <a href="http://ClinicalTrials.gov/show/NCT01402401">http://ClinicalTrials.gov/show/NCT01402401</a></td>
</tr>
<tr>
<td><strong>Study 137:</strong></td>
<td>A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology <a href="http://ClinicalTrials.gov/show/NCT01667536">http://ClinicalTrials.gov/show/NCT01667536</a></td>
</tr>
<tr>
<td><strong>Study 138:</strong></td>
<td>Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+ Metastatic Breast Cancer <a href="http://ClinicalTrials.gov/show/NCT01698918">http://ClinicalTrials.gov/show/NCT01698918</a></td>
</tr>
<tr>
<td><strong>Study 139:</strong></td>
<td>Phase I, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers <a href="http://ClinicalTrials.gov/show/NCT01563302">http://ClinicalTrials.gov/show/NCT01563302</a></td>
</tr>
<tr>
<td><strong>Study 140:</strong></td>
<td>Clinical Study of WT2725 in Patients With Advanced Solid Malignancies <a href="http://ClinicalTrials.gov/show/NCT01621542">http://ClinicalTrials.gov/show/NCT01621542</a></td>
</tr>
<tr>
<td><strong>Study 141:</strong></td>
<td>Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel Paclitaxel</td>
</tr>
<tr>
<td><strong>Study 142:</strong></td>
<td>Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC <a href="http://ClinicalTrials.gov/show/NCT01673867">http://ClinicalTrials.gov/show/NCT01673867</a></td>
</tr>
<tr>
<td><strong>Study 143:</strong></td>
<td>A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen <a href="http://ClinicalTrials.gov/show/NCT01094288">http://ClinicalTrials.gov/show/NCT01094288</a></td>
</tr>
<tr>
<td><strong>Study 144:</strong></td>
<td>Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer <a href="http://ClinicalTrials.gov/show/NCT01057810">http://ClinicalTrials.gov/show/NCT01057810</a></td>
</tr>
<tr>
<td><strong>Study 145:</strong></td>
<td>A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer <a href="http://ClinicalTrials.gov/show/NCT01641939">http://ClinicalTrials.gov/show/NCT01641939</a></td>
</tr>
<tr>
<td><strong>Study 146:</strong></td>
<td>Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer <a href="http://ClinicalTrials.gov/show/NCT01308580">http://ClinicalTrials.gov/show/NCT01308580</a></td>
</tr>
<tr>
<td><strong>Study 147:</strong></td>
<td>Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer <a href="http://ClinicalTrials.gov/show/NCT01395758">http://ClinicalTrials.gov/show/NCT01395758</a></td>
</tr>
<tr>
<td><strong>Study 148:</strong></td>
<td>Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer <a href="http://ClinicalTrials.gov/show/NCT01493843">http://ClinicalTrials.gov/show/NCT01493843</a></td>
</tr>
<tr>
<td><strong>Study 149:</strong></td>
<td>A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer <a href="http://ClinicalTrials.gov/show/NCT00907959">http://ClinicalTrials.gov/show/NCT00907959</a></td>
</tr>
<tr>
<td>Study 150:</td>
<td>Study 151:</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide (99mTc-GP) in Patients With Breast Cancer</td>
<td>Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01159405">http://ClinicalTrials.gov/show/NCT01159405</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01355484">http://ClinicalTrials.gov/show/NCT01355484</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 152:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01355497">http://ClinicalTrials.gov/show/NCT01355497</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 153:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01231802">http://ClinicalTrials.gov/show/NCT01231802</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 154:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00934856">http://ClinicalTrials.gov/show/NCT00934856</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 155:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01516307">http://ClinicalTrials.gov/show/NCT01516307</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 156:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01565083">http://ClinicalTrials.gov/show/NCT01565083</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 157:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study in Advanced Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01226485">http://ClinicalTrials.gov/show/NCT01226485</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 158:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01225172">http://ClinicalTrials.gov/show/NCT01225172</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 159:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01337765">http://ClinicalTrials.gov/show/NCT01337765</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 160:</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUX-Head&amp;Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01345682">http://ClinicalTrials.gov/show/NCT01345682</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 161:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01505166">http://ClinicalTrials.gov/show/NCT01505166</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 162:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01285609">http://ClinicalTrials.gov/show/NCT01285609</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 163:</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCHER 1009: A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01360554">http://ClinicalTrials.gov/show/NCT01360554</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 164:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004 AM3)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01357161">http://ClinicalTrials.gov/show/NCT01357161</a></td>
</tr>
</tbody>
</table>
Study 165:
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)
http://ClinicalTrials.gov/show/NCT01295632

Study 166:
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
http://ClinicalTrials.gov/show/NCT01221870

Study 167:
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
http://ClinicalTrials.gov/show/NCT01387555

Study 168:
A Study of LY3007113 in Patients With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01463631

Study 169:
Salvage Ovarian FANG Vaccine + Bevacizumab
http://ClinicalTrials.gov/show/NCT01551745

Study 170:
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
http://ClinicalTrials.gov/show/NCT01479465

Study 171:
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
http://ClinicalTrials.gov/show/NCT01472198

Study 172:
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
http://ClinicalTrials.gov/show/NCT01169584

Study 173:
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Leukemias and Related Disorders
http://ClinicalTrials.gov/show/NCT01380756

Study 174:
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
http://ClinicalTrials.gov/show/NCT00559117

Study 175:
A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
http://ClinicalTrials.gov/show/NCT01286753

Study 176:
A Study of DS-2248, in Subjects With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01288430

Study 177:
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM2)
http://ClinicalTrials.gov/show/NCT01254630

Study 178:
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
http://ClinicalTrials.gov/show/NCT01116245

Study 179:
Study of KB004 in Subjects With Hematologic Malignancies
http://ClinicalTrials.gov/show/NCT01211691

Study 180:
Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer
http://ClinicalTrials.gov/show/NCT01325428

Study 181:
Everolimus Plus Best Supportive Care vs. Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
http://ClinicalTrials.gov/show/NCT01524783
<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>182</td>
<td>A Study of LY2228820 in Patients With Advanced Cancer</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01393990">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>183</td>
<td>A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01394016">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>184</td>
<td>Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01421524">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>185</td>
<td>Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01465802">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>186</td>
<td>A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer</td>
<td><a href="http://ClinicalTrials.gov/show/NCT00994123">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>187</td>
<td>A Study of PNT2258 in Patients With Advanced Solid Tumors</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01191775">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>188</td>
<td>Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01364415">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>189</td>
<td>Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01447732">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>190</td>
<td>BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer</td>
<td><a href="http://ClinicalTrials.gov/show/NCT00962611">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>191</td>
<td>LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01125566">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>192</td>
<td>A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01658553">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>193</td>
<td>Trial of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitor</td>
<td><a href="http://ClinicalTrials.gov/show/NCT00957580">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>194</td>
<td>A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01524978">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>195</td>
<td>Study in Head and Neck Cancer</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01099358">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>196</td>
<td>A Study of Pemetrexed &amp; Carboplatin/Cisplatin or Gemcitabine &amp; Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01160744">ClinicalTrials.gov</a></td>
</tr>
<tr>
<td>197</td>
<td>A Study in Head and Neck Cancer</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01063075">ClinicalTrials.gov</a></td>
</tr>
</tbody>
</table>
**Study 198:**
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
http://ClinicalTrials.gov/show/NCT01433263

**Study 199:**
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
http://ClinicalTrials.gov/show/NCT01243762

**Study 200:**
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
http://ClinicalTrials.gov/show/NCT01624285

**Study 201:**
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
http://ClinicalTrials.gov/show/NCT01631279

**Study 202:**
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
http://ClinicalTrials.gov/show/NCT01279603

**Study 203:**
Phase 1 Study of ONT-10 in Patients With Solid Tumors
http://ClinicalTrials.gov/show/NCT01556789

**Study 204:**
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
http://ClinicalTrials.gov/show/NCT01061840

**Study 205:**
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
http://ClinicalTrials.gov/show/NCT01231594

**Study 206:**
A Study Of PF-04449913 In Select Hematologic Malignancies
http://ClinicalTrials.gov/show/NCT00953758

**Study 207:**
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
http://ClinicalTrials.gov/show/NCT01588678

**Study 208:**
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
http://ClinicalTrials.gov/show/NCT01702285

**Study 209:**
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
http://ClinicalTrials.gov/show/NCT01425008

**Study 210:**
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
http://ClinicalTrials.gov/show/NCT01594723

**Study 211:**
An Extension Study of RO5045337 in Patients Participating in Previous Cancer Studies
http://ClinicalTrials.gov/show/NCT01677780

**Study 212:**
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
http://ClinicalTrials.gov/show/NCT01345669

**Study 213:**
Vaccine Therapy in Treating Patients With Breast Cancer
http://ClinicalTrials.gov/show/NCT00524277
Study 214:
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
http://ClinicalTrials.gov/show/NCT00570323

Study 215:
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
http://ClinicalTrials.gov/show/NCT01517464

Study 216:
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01313065

Study 217:
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
http://ClinicalTrials.gov/show/NCT00932451

Study 218:
Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit
http://ClinicalTrials.gov/show/NCT01087697

Study 219:
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
http://ClinicalTrials.gov/show/NCT01374451

Study 220:
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
http://ClinicalTrials.gov/show/NCT01403064

Study 221:
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
http://ClinicalTrials.gov/show/NCT01520389

Study 222:
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01543698

Study 223:
A Study of Nilotinib Versus Imatinib in GIST Patients
http://ClinicalTrials.gov/show/NCT00785785

Study 224:
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01392521

Study 225:
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
http://ClinicalTrials.gov/show/NCT00442533

Study 226:
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSKit120212 in Selected Advanced Solid Tumor Patients
http://ClinicalTrials.gov/show/NCT01155453

Study 227:
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01577745

Study 228:
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
http://ClinicalTrials.gov/show/NCT00566618

Study 229:
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
http://ClinicalTrials.gov/show/NCT00470613
<table>
<thead>
<tr>
<th>Study 230:</th>
<th>Study 238:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma</td>
<td>A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01454076">http://ClinicalTrials.gov/show/NCT01454076</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01603979">http://ClinicalTrials.gov/show/NCT01603979</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 231:</th>
<th>Study 39:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma</td>
<td>Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01596270">http://ClinicalTrials.gov/show/NCT01596270</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01505868">http://ClinicalTrials.gov/show/NCT01505868</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 232:</th>
<th>Study 40:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of QBI-139 in Subjects With Advanced Solid Tumors</td>
<td>First in Human Trial of TAS266 in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00818831">http://ClinicalTrials.gov/show/NCT00818831</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01529307">http://ClinicalTrials.gov/show/NCT01529307</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 233:</th>
<th>Study 41:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer</td>
<td>Azacitidine and CAPOX in Metastatic Colorectal Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00925743">http://ClinicalTrials.gov/show/NCT00925743</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01193517">http://ClinicalTrials.gov/show/NCT01193517</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 234:</th>
<th>Study 42:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors</td>
<td>Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01345201">http://ClinicalTrials.gov/show/NCT01345201</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00479128">http://ClinicalTrials.gov/show/NCT00479128</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 235:</th>
<th>Study 43:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors</td>
<td>First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01277146">http://ClinicalTrials.gov/show/NCT01277146</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01097746">http://ClinicalTrials.gov/show/NCT01097746</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 236:</th>
<th>Study 44:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose-Escalation Phase 1 Study of G-202 in Patients With Advanced Solid Tumors</td>
<td>Oral Azacitidine as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01056029">http://ClinicalTrials.gov/show/NCT01056029</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01478685">http://ClinicalTrials.gov/show/NCT01478685</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 237:</th>
<th>Study 45:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors</td>
<td>A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01129349">http://ClinicalTrials.gov/show/NCT01129349</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01160211">http://ClinicalTrials.gov/show/NCT01160211</a></td>
</tr>
<tr>
<td>Study 246:</td>
<td>Study 254:</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Phase I Study of PI3 (Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01411410">http://ClinicalTrials.gov/show/NCT01411410</a></td>
<td><strong>Study of Ruxolitinib in Pancreatic Cancer Patients</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01423604">http://ClinicalTrials.gov/show/NCT01423604</a></td>
</tr>
<tr>
<td>Study 247:</td>
<td>Study 255:</td>
</tr>
<tr>
<td>Study 248:</td>
<td>Study 256:</td>
</tr>
<tr>
<td><strong>Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01517399">http://ClinicalTrials.gov/show/NCT01517399</a></td>
<td><strong>A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01507168">http://ClinicalTrials.gov/show/NCT01507168</a></td>
</tr>
<tr>
<td>Study 249:</td>
<td>Study 257:</td>
</tr>
<tr>
<td><strong>Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01438554">http://ClinicalTrials.gov/show/NCT01438554</a></td>
<td><strong>5-Azacytidine and Oxaliplatin With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01039155">http://ClinicalTrials.gov/show/NCT01039155</a></td>
</tr>
<tr>
<td>Study 250:</td>
<td>Study 258:</td>
</tr>
<tr>
<td><strong>Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01213472">http://ClinicalTrials.gov/show/NCT01213472</a></td>
<td><strong>First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor EMD 1214063 in Subjects With Advanced Solid Tumors</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01014936">http://ClinicalTrials.gov/show/NCT01014936</a></td>
</tr>
<tr>
<td>Study 251:</td>
<td>Study 259:</td>
</tr>
<tr>
<td><strong>A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01294202">http://ClinicalTrials.gov/show/NCT01294202</a></td>
<td><strong>A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01021748">http://ClinicalTrials.gov/show/NCT01021748</a></td>
</tr>
<tr>
<td>Study 252:</td>
<td>Study 260:</td>
</tr>
<tr>
<td><strong>Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01122615">http://ClinicalTrials.gov/show/NCT01122615</a></td>
<td><strong>Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01450761">http://ClinicalTrials.gov/show/NCT01450761</a></td>
</tr>
<tr>
<td>Study 253:</td>
<td>Study 261:</td>
</tr>
<tr>
<td><strong>Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01036087">http://ClinicalTrials.gov/show/NCT01036087</a></td>
<td><strong>A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)</strong>&lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01235962">http://ClinicalTrials.gov/show/NCT01235962</a></td>
</tr>
</tbody>
</table>
| Study 262: | Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery  
http://ClinicalTrials.gov/show/NCT00777673 |
| Study 263: | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor  
http://ClinicalTrials.gov/show/NCT01207492 |
| Study 264: | Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function  
http://ClinicalTrials.gov/show/NCT01443481 |
| Study 265: | Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma  
http://ClinicalTrials.gov/show/NCT01582152 |
| Study 266: | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only  
http://ClinicalTrials.gov/show/NCT01226719 |
| Study 267: | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer  
http://ClinicalTrials.gov/show/NCT01630590 |
| Study 268: | TKI258 in Castrate Resistant Prostate Cancer  
http://ClinicalTrials.gov/show/NCT00831792 |
| Study 269: | TKI258 for Metastatic Inflammatory Breast Cancer Patients  
http://ClinicalTrials.gov/show/NCT01262027 |
| Study 270: | RAD001 for Patients With Radioiodine Refractory Thyroid Cancer  
http://ClinicalTrials.gov/show/NCT00936858 |
| Study 271: | Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer  
http://ClinicalTrials.gov/show/NCT00614653 |
| Study 272: | Neoadjuvant Axitinib in Prostate Cancer  
http://ClinicalTrials.gov/show/NCT01409200 |
| Study 273: | FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer  
http://ClinicalTrials.gov/show/NCT00501410 |
| Study 274: | ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain  
http://ClinicalTrials.gov/show/NCT00981578 |
| Study 275: | A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors  
http://ClinicalTrials.gov/show/NCT01358903 |
| Study 276: | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas  
http://ClinicalTrials.gov/show/NCT01434602 |
| Study 277: | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer  
http://ClinicalTrials.gov/show/NCT00470704 |
| Study 278: | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2  
http://ClinicalTrials.gov/show/NCT01593020 |
| Study 279: | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors  
http://ClinicalTrials.gov/show/NCT01473095 |
<table>
<thead>
<tr>
<th><strong>Study 280:</strong></th>
<th><strong>Study 288:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer</td>
<td>Effect of Tivantinib on the QTC Interval in Cancer Subjects</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01008150">http://ClinicalTrials.gov/show/NCT01008150</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01699061">http://ClinicalTrials.gov/show/NCT01699061</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 281:</strong></th>
<th><strong>Study 289:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TPI 287 in Breast Cancer Metastatic to the Brain</td>
<td>A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01332630">http://ClinicalTrials.gov/show/NCT01332630</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01455532">http://ClinicalTrials.gov/show/NCT01455532</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 282:</strong></th>
<th><strong>Study 290:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of PM060184 in Patients With Advanced Solid Tumors</td>
<td>Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650 AM1)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01299636">http://ClinicalTrials.gov/show/NCT01299636</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01463696">http://ClinicalTrials.gov/show/NCT01463696</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 283:</strong></th>
<th><strong>Study 291:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene</td>
<td>An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVENTM in Subjects With Cancer Who Also Have Impaired Renal Function</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00932893">http://ClinicalTrials.gov/show/NCT00932893</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01418677">http://ClinicalTrials.gov/show/NCT01418677</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 284:</strong></th>
<th><strong>Study 292:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies</td>
<td>First in Man Study of SAR566658 Administered Every 3 Weeks in Patients With DS6-positive and Refractory Solid Tumors</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01179399">http://ClinicalTrials.gov/show/NCT01179399</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01156870">http://ClinicalTrials.gov/show/NCT01156870</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 285:</strong></th>
<th><strong>Study 293:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors</td>
<td>BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01110486">http://ClinicalTrials.gov/show/NCT01110486</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01248247">http://ClinicalTrials.gov/show/NCT01248247</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 286:</strong></th>
<th><strong>Study 294:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours</td>
<td>Neoadjuvant Ipilimumab in Prostate Cancer</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01281592">http://ClinicalTrials.gov/show/NCT01281592</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01194271">http://ClinicalTrials.gov/show/NCT01194271</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Study 287:</strong></th>
<th><strong>Study 295:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies</td>
<td>A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01613261">http://ClinicalTrials.gov/show/NCT01613261</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01283516">http://ClinicalTrials.gov/show/NCT01283516</a></td>
</tr>
<tr>
<td>Study</td>
<td>Title</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>296</td>
<td>Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment</td>
</tr>
<tr>
<td>297</td>
<td>Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy</td>
</tr>
<tr>
<td>298</td>
<td>Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC)</td>
</tr>
<tr>
<td>299</td>
<td>Neo-Adjuvant Study in Triple Negative Breast Cancer Patients</td>
</tr>
<tr>
<td>300</td>
<td>Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax</td>
</tr>
<tr>
<td>301</td>
<td>Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer</td>
</tr>
<tr>
<td>302</td>
<td>Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases</td>
</tr>
<tr>
<td>303</td>
<td>Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel</td>
</tr>
<tr>
<td>304</td>
<td>Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias</td>
</tr>
<tr>
<td>305</td>
<td>Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer</td>
</tr>
<tr>
<td>306</td>
<td>Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer</td>
</tr>
<tr>
<td>307</td>
<td>Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors</td>
</tr>
<tr>
<td>308</td>
<td>Trial of Poor Performance Status Patients (ToPPS)</td>
</tr>
<tr>
<td>309</td>
<td>Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients</td>
</tr>
<tr>
<td>310</td>
<td>Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy</td>
</tr>
<tr>
<td>311</td>
<td>Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy</td>
</tr>
<tr>
<td>312</td>
<td>Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors</td>
</tr>
</tbody>
</table>
**Study 313:**
Bendamustine and Bevacizumab for Advanced Cancers
http://ClinicalTrials.gov/show/NCT01152203

**Study 314:**
Panitumumab Pediatric Study
http://ClinicalTrials.gov/show/NCT00658658

**Study 315:**
Multiple Ascending Dose (MDX1105-01)
http://ClinicalTrials.gov/show/NCT00729664

**Study 316:**
Combination Trial MSC1936369B With Temsirolimus
http://ClinicalTrials.gov/show/NCT01378377

**Study 317:**
A Phase I Dose-Escalation and PK Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
http://ClinicalTrials.gov/show/NCT01204164

**Study 318:**
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
http://ClinicalTrials.gov/show/NCT01180959

**Study 319:**
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
http://ClinicalTrials.gov/show/NCT01263769

**Study 320:**
Maximum Androgen Depletion
http://ClinicalTrials.gov/show/NCT01254864

**Study 321:**
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
http://ClinicalTrials.gov/show/NCT01500161

**Study 322:**
REGN910 (SAR307746) and Aflibercept (“Ziv-aflibercept” in the U.S.) in Patients With Advanced Solid Malignancies
http://ClinicalTrials.gov/show/NCT01688960

**Study 323:**
GSK1120212 Rollover Study
http://ClinicalTrials.gov/show/NCT01376310

**Study 324:**
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
http://ClinicalTrials.gov/show/NCT01392183

**Study 325:**
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01185366

**Study 326:**
Preventing Sexual Dysfunction With Aromatase Inhibitors
http://ClinicalTrials.gov/show/NCT01603303

**Study 327:**
The Role of Ghrelin in Cancer Cachexia
http://ClinicalTrials.gov/show/NCT01505764

**Study 328:**
Multiple Ascending Dose of BMS-911543
http://ClinicalTrials.gov/show/NCT01236352

**Study 329:**
Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
http://ClinicalTrials.gov/show/NCT01266031

**Study 330:**
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
http://ClinicalTrials.gov/show/NCT01110876
**Study 331:**
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
http://ClinicalTrials.gov/show/NCT01614990

**Study 332:**
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
http://ClinicalTrials.gov/show/NCT01523171

**Study 333:**
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocytemia
http://ClinicalTrials.gov/show/NCT01420783

**Study 334:**
Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Argininosuccinate Synthetase Deficient Advanced Tumors
http://ClinicalTrials.gov/show/NCT01665183

**Study 335:**
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
http://ClinicalTrials.gov/show/NCT01183663

**Study 336:**
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
http://ClinicalTrials.gov/show/NCT00942734

**Study 337:**
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
http://ClinicalTrials.gov/show/NCT01110473

**Study 338:**
Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
http://ClinicalTrials.gov/show/NCT01208103

**Study 339:**
Sorafenib Long Term Extension Program (STEP)
http://ClinicalTrials.gov/show/NCT00625378

**Study 340:**
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
http://ClinicalTrials.gov/show/NCT01202409

**Study 341:**
Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin
http://ClinicalTrials.gov/show/NCT01198028

**Study 342:**
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
http://ClinicalTrials.gov/show/NCT01427205

**Study 343:**
Clinical Trial of ARQ 761 in Advanced Solid Tumors
http://ClinicalTrials.gov/show/NCT01502800

**Study 344:**
Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer
http://ClinicalTrials.gov/show/NCT01640730

**Study 345:**
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
http://ClinicalTrials.gov/show/NCT01262651

**Study 346:**
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
http://ClinicalTrials.gov/show/NCT01585987
Study 347:
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
http://ClinicalTrials.gov/show/NCT01606579

Study 348:
Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01444716

Study 349:
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
http://ClinicalTrials.gov/show/NCT00929188

Study 350:
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
http://ClinicalTrials.gov/show/NCT01226277

Study 351:
Phase 1 and 2 Study of PX-866 and Cetuximab
http://ClinicalTrials.gov/show/NCT01252628

Study 352:
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
http://ClinicalTrials.gov/show/NCT01593228

Study 353:
A Phase 1 Study of LY2787106 in Cancer and Anemia
http://ClinicalTrials.gov/show/NCT01340976

Study 354:
Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
http://ClinicalTrials.gov/show/NCT01514864

Study 355:
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT01664910

Study 356:
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
http://ClinicalTrials.gov/show/NCT01072175

Study 357:
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols
http://ClinicalTrials.gov/show/NCT01178411

Study 358:
Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT00888015

Study 359:
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
http://ClinicalTrials.gov/show/NCT01587040

Study 360:
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nalobine in Patients With Relapsed/Refractory Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT01094860

Study 361:
Study of REGN910 (SAR307746)
http://ClinicalTrials.gov/show/NCT01271972

Study 362:
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
http://ClinicalTrials.gov/show/NCT01120457

Study 363:
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
http://ClinicalTrials.gov/show/NCT01304784
Study 364:
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
http://ClinicalTrials.gov/show/NCT01090414

Study 365:
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
http://ClinicalTrials.gov/show/NCT01200485

Study 366:
HepaSphere/QuadraspHERE Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
http://ClinicalTrials.gov/show/NCT01387932

Study 367:
A Study of LY2510924 in Patients With Extensive-Stage Small Cell Lung Carcinoma
http://ClinicalTrials.gov/show/NCT01439568

Study 368:
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
http://ClinicalTrials.gov/show/NCT01597908

Study 369:
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
http://ClinicalTrials.gov/show/NCT01523587

Study 370:
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
http://ClinicalTrials.gov/show/NCT01147809

Study 371:
Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies
http://ClinicalTrials.gov/show/NCT00439556

Study 372:
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01063907

Study 373:
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
http://ClinicalTrials.gov/show/NCT01439152

Study 374:
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma, a Type of Blood Cancer
http://ClinicalTrials.gov/show/NCT01499303

Study 375:
Preoperative Treatment With Cetuximab and/or IMC-A12
http://ClinicalTrials.gov/show/NCT00957853

Study 376:
Treatment of Blood Clots in Children With Cancer
http://ClinicalTrials.gov/show/NCT00952380

Study 377:
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
http://ClinicalTrials.gov/show/NCT00882609

Study 378:
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
http://ClinicalTrials.gov/show/NCT00998192

Study 379:
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder, Urethra, Ureter, or Renal Pelvis Carcinoma
http://ClinicalTrials.gov/show/NCT01282463
Study 380:
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
http://ClinicalTrials.gov/show/NCT01125800

Study 381:
Phase II FANG in Advanced Melanoma
http://ClinicalTrials.gov/show/NCT01453361

Study 382:
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials
http://ClinicalTrials.gov/show/NCT00828919

Study 383:
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
http://ClinicalTrials.gov/show/NCT00506142

Study 384:
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
http://ClinicalTrials.gov/show/NCT01378975

Study 385:
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
http://ClinicalTrials.gov/show/NCT00911326

Study 386:
Study of ACE-041 in Patients With Squamous Cell Carcinoma of the Head and Neck
http://ClinicalTrials.gov/show/NCT01458392

Study 387:
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
http://ClinicalTrials.gov/show/NCT01490723

Study 388:
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01478048

Study 389:
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01239797

Study 390:
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01335399

Study 391:
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
http://ClinicalTrials.gov/show/NCT00916409

Study 392:
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
http://ClinicalTrials.gov/show/NCT01002248

Study 393:
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
http://ClinicalTrials.gov/show/NCT01337752

Study 394:
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01484275

Study 395:
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01391130

Study 396:
BT062 in Combination With Lenalidomide/ Dexamethasone in Patients With Multiple Myeloma
http://ClinicalTrials.gov/show/NCT01638936
| Study 397: | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)  
http://ClinicalTrials.gov/show/NCT01167166 |
| Study 398: | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma  
http://ClinicalTrials.gov/show/NCT01223027 |
| Study 399: | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma  
http://ClinicalTrials.gov/show/NCT01441414 |
| Study 400: | Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01383928 |
| Study 401: | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT00821249 |
| Study 402: | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01323751 |
| Study 403: | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01101594 |
| Study 404: | Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function  
http://ClinicalTrials.gov/show/NCT01393964 |
| Study 405: | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)  
http://ClinicalTrials.gov/show/NCT00471497 |
| Study 406: | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)  
http://ClinicalTrials.gov/show/NCT01191801 |
| Study 407: | A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01248923 |
| Study 408: | Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function  
http://ClinicalTrials.gov/show/NCT01575925 |
| Study 409: | IMGN901 in Combination With Lenalidomide and Dexamethasone  
http://ClinicalTrials.gov/show/NCT00991562 |
| Study 410: | Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients  
http://ClinicalTrials.gov/show/NCT01568866 |
| Study 411: | Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01302886 |
| Study 412: | A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma  
http://ClinicalTrials.gov/show/NCT01456689 |
<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>413:</td>
<td>Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma</td>
</tr>
<tr>
<td>414:</td>
<td>Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia</td>
</tr>
<tr>
<td>415:</td>
<td>Ipilimumab for Uveal Melanoma</td>
</tr>
<tr>
<td>417:</td>
<td>A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma</td>
</tr>
<tr>
<td>418:</td>
<td>A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas</td>
</tr>
<tr>
<td>419:</td>
<td>Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma</td>
</tr>
<tr>
<td>421:</td>
<td>Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma</td>
</tr>
<tr>
<td>422:</td>
<td>Induction Therapy—Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Parasal Sinuses</td>
</tr>
<tr>
<td>423:</td>
<td>Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma</td>
</tr>
<tr>
<td>424:</td>
<td>Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)</td>
</tr>
<tr>
<td>425:</td>
<td>Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non–Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia</td>
</tr>
<tr>
<td>426:</td>
<td>Open-Label Study of TPI 287 for Patients With Metastatic Melanoma</td>
</tr>
<tr>
<td>427:</td>
<td>A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>428:</td>
<td>Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)</td>
</tr>
<tr>
<td>429:</td>
<td>Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients</td>
</tr>
<tr>
<td>Study 430:</td>
<td>Lenalidomide/Bortezomib/Dexamethasone &amp; CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01531998">http://ClinicalTrials.gov/show/NCT01531998</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 431:</th>
<th>Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01301807">http://ClinicalTrials.gov/show/NCT01301807</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 432:</th>
<th>A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01464034">http://ClinicalTrials.gov/show/NCT01464034</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 433:</th>
<th>Arry-520 + Carfilzomib for Multiple Myeloma (MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01372540">http://ClinicalTrials.gov/show/NCT01372540</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 434:</th>
<th>Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01208662">http://ClinicalTrials.gov/show/NCT01208662</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 435:</th>
<th>Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01258933">http://ClinicalTrials.gov/show/NCT01258933</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 436:</th>
<th>Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01380106">http://ClinicalTrials.gov/show/NCT01380106</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 437:</th>
<th>Acupuncture for Chemo-Induced Peripheral Neuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00891618">http://ClinicalTrials.gov/show/NCT00891618</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 438:</th>
<th>Busulfan Plus Melphalan Versus Melphalan</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01413178">http://ClinicalTrials.gov/show/NCT01413178</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 439:</th>
<th>Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01014208">http://ClinicalTrials.gov/show/NCT01014208</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 440:</th>
<th>A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01369329">http://ClinicalTrials.gov/show/NCT01369329</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 441:</th>
<th>Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01339052">http://ClinicalTrials.gov/show/NCT01339052</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 442:</th>
<th>Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01092728">http://ClinicalTrials.gov/show/NCT01092728</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 443:</th>
<th>Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00338377">http://ClinicalTrials.gov/show/NCT00338377</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 444:</th>
<th>A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01466153">http://ClinicalTrials.gov/show/NCT01466153</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 445:</th>
<th>SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01352520">http://ClinicalTrials.gov/show/NCT01352520</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 446:</th>
<th>Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01668784">http://ClinicalTrials.gov/show/NCT01668784</a></td>
</tr>
</tbody>
</table>
**Study 447:**
A Study in Recurrent Glioblastoma (GB)
http://ClinicalTrials.gov/show/NCT01582269

**Study 448:**
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
http://ClinicalTrials.gov/show/NCT01136967

**Study 449:**
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
http://ClinicalTrials.gov/show/NCT00908752

**Study 450:**
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
http://ClinicalTrials.gov/show/NCT01028222

**Study 451:**
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
http://ClinicalTrials.gov/show/NCT01546571

**Study 452:**
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
http://ClinicalTrials.gov/show/NCT01343277

**Study 453:**
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
http://ClinicalTrials.gov/show/NCT01592045

**Study 454:**
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01327053

**Study 455:**
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
http://ClinicalTrials.gov/show/NCT01136733

**Study 456:**
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
http://ClinicalTrials.gov/show/NCT01260506

**Study 457:**
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
http://ClinicalTrials.gov/show/NCT01339260

**Study 458:**
A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma
http://ClinicalTrials.gov/show/NCT01673386

**Study 459:**
Philips Pivotal Clinical Trial for MRI-HIFU of Uterine Fibroids
http://ClinicalTrials.gov/show/NCT01504308

**Study 460:**
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
http://ClinicalTrials.gov/show/NCT00585312

**Study 461:**
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
http://ClinicalTrials.gov/show/NCT01473901

**Study 462:**
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
http://ClinicalTrials.gov/show/NCT01403610
<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>463</td>
<td>A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01632228">http://ClinicalTrials.gov/show/NCT01632228</a></td>
</tr>
<tr>
<td>464</td>
<td>Macitentan in Combo With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01499251">http://ClinicalTrials.gov/show/NCT01499251</a></td>
</tr>
<tr>
<td>465</td>
<td>Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01032070">http://ClinicalTrials.gov/show/NCT01032070</a></td>
</tr>
<tr>
<td>466</td>
<td>An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01559844">http://ClinicalTrials.gov/show/NCT01559844</a></td>
</tr>
<tr>
<td>467</td>
<td>A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01140347">http://ClinicalTrials.gov/show/NCT01140347</a></td>
</tr>
<tr>
<td>468</td>
<td>Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01265576">http://ClinicalTrials.gov/show/NCT01265576</a></td>
</tr>
<tr>
<td>469</td>
<td>ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01287585">http://ClinicalTrials.gov/show/NCT01287585</a></td>
</tr>
<tr>
<td>470</td>
<td>Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01397708">http://ClinicalTrials.gov/show/NCT01397708</a></td>
</tr>
<tr>
<td>471</td>
<td>A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01667419">http://ClinicalTrials.gov/show/NCT01667419</a></td>
</tr>
<tr>
<td>472</td>
<td>A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01519323">http://ClinicalTrials.gov/show/NCT01519323</a></td>
</tr>
<tr>
<td>473</td>
<td>A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01656642">http://ClinicalTrials.gov/show/NCT01656642</a></td>
</tr>
<tr>
<td>474</td>
<td>A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01584648">http://ClinicalTrials.gov/show/NCT01584648</a></td>
</tr>
<tr>
<td>475</td>
<td>A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01227551">http://ClinicalTrials.gov/show/NCT01227551</a></td>
</tr>
<tr>
<td>476</td>
<td>Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01489059">http://ClinicalTrials.gov/show/NCT01489059</a></td>
</tr>
<tr>
<td>477</td>
<td>Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01211262">http://ClinicalTrials.gov/show/NCT01211262</a></td>
</tr>
</tbody>
</table>
| Study 478: | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma  
http://ClinicalTrials.gov/show/NCT00984464 |
| Study 479: | A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma  
http://ClinicalTrials.gov/show/NCT01264380 |
| Study 480: | Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH  
http://ClinicalTrials.gov/show/NCT01092585 |
| Study 481: | Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma  
http://ClinicalTrials.gov/show/NCT01621490 |
| Study 482: | Extension of Study ZPV-200  
http://ClinicalTrials.gov/show/NCT01631903 |
| Study 483: | Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids  
http://ClinicalTrials.gov/show/NCT01451424 |
| Study 484: | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia (B-All)  
http://ClinicalTrials.gov/show/NCT01685021 |
| Study 485: | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed  
http://ClinicalTrials.gov/show/NCT01098266 |
| Study 486: | A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)  
http://ClinicalTrials.gov/show/NCT01201915 |
| Study 487: | Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia  
http://ClinicalTrials.gov/show/NCT00782067 |
| Study 488: | A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap  
http://ClinicalTrials.gov/show/NCT00814073 |
| Study 489: | A Study of IMC-3G3 in Soft Tissue Sarcoma  
http://ClinicalTrials.gov/show/NCT01185964 |
| Study 490: | Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome  
http://ClinicalTrials.gov/show/NCT01511978 |
| Study 491: | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma  
http://ClinicalTrials.gov/show/NCT00998322 |
| Study 492: | A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment  
http://ClinicalTrials.gov/show/NCT00210665 |
| Study 493: | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma  
http://ClinicalTrials.gov/show/NCT01514188 |
<table>
<thead>
<tr>
<th>Study 494:</th>
<th>BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01034631">http://ClinicalTrials.gov/show/NCT01034631</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 495:</th>
<th>Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00671801">http://ClinicalTrials.gov/show/NCT00671801</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 496:</th>
<th>Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00555399">http://ClinicalTrials.gov/show/NCT00555399</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 497:</th>
<th>A Phase I/II Study of TPI 287-Temozolomide Combination in Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01067066">http://ClinicalTrials.gov/show/NCT01067066</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 498:</th>
<th>A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00611208">http://ClinicalTrials.gov/show/NCT00611208</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 499:</th>
<th>A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01232556">http://ClinicalTrials.gov/show/NCT01232556</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 500:</th>
<th>Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01295710">http://ClinicalTrials.gov/show/NCT01295710</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 501:</th>
<th>A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+ RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin’s Lymphoma (GADOLIN)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01059630">http://ClinicalTrials.gov/show/NCT01059630</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 502:</th>
<th>High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01266603">http://ClinicalTrials.gov/show/NCT01266603</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 503:</th>
<th>Study of Weekly LOC-paclitaxel Injection for Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01039844">http://ClinicalTrials.gov/show/NCT01039844</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 504:</th>
<th>GSK2118436 and GSK1120212</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01619774">http://ClinicalTrials.gov/show/NCT01619774</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 505:</th>
<th>Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00539591">http://ClinicalTrials.gov/show/NCT00539591</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 506:</th>
<th>Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01127594">http://ClinicalTrials.gov/show/NCT01127594</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 507:</th>
<th>Safety and Efficacy of Telavancin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01321879">http://ClinicalTrials.gov/show/NCT01321879</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 508:</th>
<th>Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00931918">http://ClinicalTrials.gov/show/NCT00931918</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 509:</th>
<th>Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00790036">http://ClinicalTrials.gov/show/NCT00790036</a></td>
</tr>
</tbody>
</table>
Study 510:
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
http://ClinicalTrials.gov/show/NCT01321541

Study 511:
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
http://ClinicalTrials.gov/show/NCT01460160

Study 512:
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
http://ClinicalTrials.gov/show/NCT01414855

Study 513:
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)
http://ClinicalTrials.gov/show/NCT01414205

Study 514:
A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01421667

Study 515:
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL)
http://ClinicalTrials.gov/show/NCT01294579

Study 516:
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
http://ClinicalTrials.gov/show/NCT01241500

Study 517:
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML-CP (Chronic Myelogenous Leukemia-Chronic Phase)
http://ClinicalTrials.gov/show/NCT00718263

Study 518:
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01569295

Study 519:
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01303796

Study 520:
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
http://ClinicalTrials.gov/show/NCT00711035

Study 521:
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01539512

Study 522:
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
http://ClinicalTrials.gov/show/NCT00777036

Study 523:
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
http://ClinicalTrials.gov/show/NCT01476787

Study 524:
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
http://ClinicalTrials.gov/show/NCT01539291

Study 525:
Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy
http://ClinicalTrials.gov/show/NCT00715611
<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>526</td>
<td>Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01055028">http://ClinicalTrials.gov/show/NCT01055028</a></td>
</tr>
<tr>
<td>527</td>
<td>Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01462630">http://ClinicalTrials.gov/show/NCT01462630</a></td>
</tr>
<tr>
<td>528</td>
<td>Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01330966">http://ClinicalTrials.gov/show/NCT01330966</a></td>
</tr>
<tr>
<td>529</td>
<td>A Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01261312">http://ClinicalTrials.gov/show/NCT01261312</a></td>
</tr>
<tr>
<td>530</td>
<td>Phase I/II Study of DFP-10917 in Patients With Acute Leukemia  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01702155">http://ClinicalTrials.gov/show/NCT01702155</a></td>
</tr>
<tr>
<td>531</td>
<td>Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01197560">http://ClinicalTrials.gov/show/NCT01197560</a></td>
</tr>
<tr>
<td>532</td>
<td>Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT00603668">http://ClinicalTrials.gov/show/NCT00603668</a></td>
</tr>
<tr>
<td>533</td>
<td>Dasatinib Combo With SMO Inhibitor (BMS-833923)  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01218477">http://ClinicalTrials.gov/show/NCT01218477</a></td>
</tr>
<tr>
<td>534</td>
<td>Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01433731">http://ClinicalTrials.gov/show/NCT01433731</a></td>
</tr>
<tr>
<td>535</td>
<td>A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01578707">http://ClinicalTrials.gov/show/NCT01578707</a></td>
</tr>
<tr>
<td>536</td>
<td>TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01300611">http://ClinicalTrials.gov/show/NCT01300611</a></td>
</tr>
<tr>
<td>537</td>
<td>A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01390337">http://ClinicalTrials.gov/show/NCT01390337</a></td>
</tr>
<tr>
<td>538</td>
<td>A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01599949">http://ClinicalTrials.gov/show/NCT01599949</a></td>
</tr>
<tr>
<td>539</td>
<td>A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01569750">http://ClinicalTrials.gov/show/NCT01569750</a></td>
</tr>
<tr>
<td>540</td>
<td>A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01468467">http://ClinicalTrials.gov/show/NCT01468467</a></td>
</tr>
<tr>
<td>541</td>
<td>An Open Label Study to Evaluate the Safety and Efficacy of Two Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia  &lt;br&gt;<a href="http://ClinicalTrials.gov/show/NCT01565668">http://ClinicalTrials.gov/show/NCT01565668</a></td>
</tr>
</tbody>
</table>
**Study 542:**
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
http://ClinicalTrials.gov/show/NCT01611090

**Study 543:**
A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01578499

**Study 544:**
A Study in Participants With Acute Leukemia
http://ClinicalTrials.gov/show/NCT01214603

**Study 545:**
Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01393106

**Study 546:**
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
http://ClinicalTrials.gov/show/NCT00520208

**Study 547:**
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
http://ClinicalTrials.gov/show/NCT00910910

**Study 548:**
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
http://ClinicalTrials.gov/show/NCT01519011

**Study 549:**
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01410513

**Study 550:**
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
http://ClinicalTrials.gov/show/NCT01693614

**Study 551:**
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
http://ClinicalTrials.gov/show/NCT01149915

**Study 552:**
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
http://ClinicalTrials.gov/show/NCT01363817

**Study 553:**
Safety and Tolerability of AZD1208 and the Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
http://ClinicalTrials.gov/show/NCT01489722

**Study 554:**
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
http://ClinicalTrials.gov/show/NCT01358734

**Study 555:**
Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649 AM3)
http://ClinicalTrials.gov/show/NCT01451437

**Study 556:**
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
http://ClinicalTrials.gov/show/NCT01546038
Study 557:
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
http://ClinicalTrials.gov/show/NCT01177540

Study 558:
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01402440

Study 559:
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
http://ClinicalTrials.gov/show/NCT01134341

Study 560:
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
http://ClinicalTrials.gov/show/NCT00774345

Study 561:
A Phase Ib/Ii, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT00946647

Study 562:
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01074047

Study 563:
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
http://ClinicalTrials.gov/show/NCT01439347

Study 564:
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT01088048

Study 565:
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
http://ClinicalTrials.gov/show/NCT01398462

Study 566:
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01482962

Study 567:
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
http://ClinicalTrials.gov/show/NCT00911066

Study 568:
Phase II Study of Crenolanib in Subjects With Relapsed AML With FLT3-D835 Activating Mutations
http://ClinicalTrials.gov/show/NCT01522469

Study 569:
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01221571

Study 570:
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01242774

Study 571:
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT01478074
Study 572:
Nilotinib and LDE225 in the Treatment of Phase Chronic Myeloid Leukemia Patients Who Developed Resistance to Prior Therapy
http://ClinicalTrials.gov/show/NCT01456676

Study 573:
SAR3419 in Acute Lymphoblastic Leukemia
http://ClinicalTrials.gov/show/NCT01440179

Study 574:
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01466179

Study 575:
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
http://ClinicalTrials.gov/show/NCT01657682

Study 576:
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
http://ClinicalTrials.gov/show/NCT00590187

Study 577:
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
http://ClinicalTrials.gov/show/NCT01200589

Study 578:
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT01635296

Study 579:
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT01691898

Study 580:
Clinical Study of PM01183 in Patients With Acute Leukemia
http://ClinicalTrials.gov/show/NCT01314599

Study 581:
Bortezomib and Rituximab for Patients With Waldenstrom’s Macroglobulinemia
http://ClinicalTrials.gov/show/NCT00492050

Study 582:
Pomalidomide for Relapse/Refractory Waldenstrom’s
http://ClinicalTrials.gov/show/NCT01198067

Study 583:
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT01614197

Study 584:
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
http://ClinicalTrials.gov/show/NCT01254890

Study 585:
Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)
http://ClinicalTrials.gov/show/NCT01636609

Study 586:
SAHA + CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma
http://ClinicalTrials.gov/show/NCT00787527

Study 587:
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01371630
Study 588:
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01038635

Study 589:
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT01169636

Study 590:
Phase I/II-Dasatinib and Decitabine
http://ClinicalTrials.gov/show/NCT01498445

Study 591:
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
http://ClinicalTrials.gov/show/NCT00968253

Study 592:
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
http://ClinicalTrials.gov/show/NCT01202877

Study 593:
PKC412 and 5-Azacytidine
http://ClinicalTrials.gov/show/NCT01202877

Study 594:
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
http://ClinicalTrials.gov/show/NCT00943943

Study 595:
Stem Cell Collection With Ofatumumab
http://ClinicalTrials.gov/show/NCT01329900

Study 596:
Bortezomib (Velcade) Plus Rituximab–HyperCVAD in Patients With Mantle Cell Lymphoma
http://ClinicalTrials.gov/show/NCT00477412

Study 597:
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
http://ClinicalTrials.gov/show/NCT00656617

Study 598:
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
http://ClinicalTrials.gov/show/NCT00703820

Study 599:
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT01168921

Study 600:
Study of Dasatinib in Patients With Chronic Myelogenous Leukemia
http://ClinicalTrials.gov/show/NCT00254423

Study 601:
Hyper CVAD Plus Ofatumumab in CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
http://ClinicalTrials.gov/show/NCT01363128

Study 602:
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
http://ClinicalTrials.gov/show/NCT00899431

Study 603:
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
http://ClinicalTrials.gov/show/NCT00654732

Study 604:
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
http://ClinicalTrials.gov/show/NCT01590732
<table>
<thead>
<tr>
<th>Study 605:</th>
<th>Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01446133">http://ClinicalTrials.gov/show/NCT01446133</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 606:</th>
<th>Eltrombopag for Management of Thrombocytopenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01428635">http://ClinicalTrials.gov/show/NCT01428635</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 607:</th>
<th>A Study of the HSP90 Inhibitor AUY922</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01485536">http://ClinicalTrials.gov/show/NCT01485536</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 608:</th>
<th>Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00129740">http://ClinicalTrials.gov/show/NCT00129740</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 609:</th>
<th>Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01272245">http://ClinicalTrials.gov/show/NCT01272245</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 610:</th>
<th>Study of Bortezomib in Combination With Cyclophosphamide and Rituximab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00958256">http://ClinicalTrials.gov/show/NCT00958256</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 611:</th>
<th>Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01253460">http://ClinicalTrials.gov/show/NCT01253460</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 612:</th>
<th>Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01409161">http://ClinicalTrials.gov/show/NCT01409161</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 613:</th>
<th>Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00948064">http://ClinicalTrials.gov/show/NCT00948064</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 614:</th>
<th>A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01411267">http://ClinicalTrials.gov/show/NCT01411267</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 615:</th>
<th>Ponatinib-Frontline for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01570868">http://ClinicalTrials.gov/show/NCT01570868</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 616:</th>
<th>Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01319981">http://ClinicalTrials.gov/show/NCT01319981</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 617:</th>
<th>Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01424982">http://ClinicalTrials.gov/show/NCT01424982</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 618:</th>
<th>Lenalidomide Plus Rituximab for Indolent Non-Hodgkin’s Lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00695786">http://ClinicalTrials.gov/show/NCT00695786</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 619:</th>
<th>Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01243190">http://ClinicalTrials.gov/show/NCT01243190</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 620:</th>
<th>2CDA With Rituximab in Hairy Cell Leukemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00412594">http://ClinicalTrials.gov/show/NCT00412594</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 621:</th>
<th>Pilot Phase II-Erlotinib for Acute Myeloid Leukemia (AML)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01664897">http://ClinicalTrials.gov/show/NCT01664897</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 622:</th>
<th>E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01692197">http://ClinicalTrials.gov/show/NCT01692197</a></td>
</tr>
</tbody>
</table>
Study 623:
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
http://ClinicalTrials.gov/show/NCT01396499

Study 624:
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
http://ClinicalTrials.gov/show/NCT00940602

Study 625:
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
http://ClinicalTrials.gov/show/NCT01029262

Study 626:
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
http://ClinicalTrials.gov/show/NCT01496495

Study 627:
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
http://ClinicalTrials.gov/show/NCT01252108

Study 628:
Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"
http://ClinicalTrials.gov/show/NCT01677195

Study 629:
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
http://ClinicalTrials.gov/show/NCT00903760

Study 630:
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease
http://ClinicalTrials.gov/show/NCT01582061

Study 631:
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocytopenia MF
http://ClinicalTrials.gov/show/NCT01423851

Study 632:
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
http://ClinicalTrials.gov/show/NCT01635764

Study 633:
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
http://ClinicalTrials.gov/show/NCT01266070

Diabetes
(92 clinical trials recruiting)

Study 1:
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01617434

Study 2:
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01541215

Study 3:
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT00658021

Study 4:
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
http://ClinicalTrials.gov/show/NCT01664247
<p>| Study 5: | The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy |
| Study 6: | A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin |
| Study 7: | Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine |
| Study 8: | A Study in Patients With Type 2 Diabetes Mellitus |
| Study 9: | Study to Assess Safety &amp; Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083) |
| Study 10: | The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy |
| Study 11: | Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes |
| Study 12: | Reseaching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) |
| Study 13: | CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes |
| Study 14: | A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication |
| Study 15: | A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) |
| Study 16: | A Study in Patients With Type I Diabetes Mellitus |
| Study 17: | BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients. |
| Study 18: | A Study in Participants With Type 2 Diabetes Mellitus |
| Study 19: | A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus |
| Study 20: | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01144338">http://ClinicalTrials.gov/show/NCT01144338</a></td>
</tr>
<tr>
<td>22</td>
<td>Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome</td>
<td><a href="http://ClinicalTrials.gov/show/NCT00968708">http://ClinicalTrials.gov/show/NCT00968708</a></td>
</tr>
<tr>
<td>23</td>
<td>Single Ascending Dose Trial in Patients With Type 2 Diabetes</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01492465">http://ClinicalTrials.gov/show/NCT01492465</a></td>
</tr>
<tr>
<td>24</td>
<td>Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01496430">http://ClinicalTrials.gov/show/NCT01496430</a></td>
</tr>
<tr>
<td>25</td>
<td>A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01624259">http://ClinicalTrials.gov/show/NCT01624259</a></td>
</tr>
<tr>
<td>26</td>
<td>Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01699737">http://ClinicalTrials.gov/show/NCT01699737</a></td>
</tr>
<tr>
<td>27</td>
<td>Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01472185">http://ClinicalTrials.gov/show/NCT01472185</a></td>
</tr>
<tr>
<td>28</td>
<td>Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01494987">http://ClinicalTrials.gov/show/NCT01494987</a></td>
</tr>
<tr>
<td>29</td>
<td>Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01103284">http://ClinicalTrials.gov/show/NCT01103284</a></td>
</tr>
<tr>
<td>30</td>
<td>A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01500798">http://ClinicalTrials.gov/show/NCT01500798</a></td>
</tr>
<tr>
<td>31</td>
<td>Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01456195">http://ClinicalTrials.gov/show/NCT01456195</a></td>
</tr>
<tr>
<td>32</td>
<td>Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01481116">http://ClinicalTrials.gov/show/NCT01481116</a></td>
</tr>
<tr>
<td>33</td>
<td>Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01609582">http://ClinicalTrials.gov/show/NCT01609582</a></td>
</tr>
<tr>
<td>34</td>
<td>Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01451398">http://ClinicalTrials.gov/show/NCT01451398</a></td>
</tr>
<tr>
<td>35</td>
<td>A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01621178">http://ClinicalTrials.gov/show/NCT01621178</a></td>
</tr>
<tr>
<td>36</td>
<td>A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01042769">http://ClinicalTrials.gov/show/NCT01042769</a></td>
</tr>
</tbody>
</table>
| Study 37: | Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment  
http://ClinicalTrials.gov/show/NCT01620489 |
|---|---|
| Study 38: | Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin  
http://ClinicalTrials.gov/show/NCT01517373 |
| Study 39: | A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170 AM1)  
http://ClinicalTrials.gov/show/NCT01472367 |
| Study 40: | Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease  
http://ClinicalTrials.gov/show/NCT00642616 |
| Study 41: | A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes  
http://ClinicalTrials.gov/show/NCT01665352 |
| Study 42: | A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy  
http://ClinicalTrials.gov/show/NCT01649297 |
| Study 43: | A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone  
http://ClinicalTrials.gov/show/NCT01555164 |
| Study 44: | A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)  
http://ClinicalTrials.gov/show/NCT01477853 |
| Study 45: | Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period  
http://ClinicalTrials.gov/show/NCT01445951 |
| Study 46: | Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy  
http://ClinicalTrials.gov/show/NCT01499095 |
| Study 47: | Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260 AM3)  
http://ClinicalTrials.gov/show/NCT01462266 |
| Study 48: | Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes  
http://ClinicalTrials.gov/show/NCT00322478 |
| Study 49: | Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus  
http://ClinicalTrials.gov/show/NCT01069965 |
| Study 50: | AMG 151 Amgen Protocol Number 20100761  
http://ClinicalTrials.gov/show/NCT01464437 |
| Study 51: | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes  
http://ClinicalTrials.gov/show/NCT01204775 |
<table>
<thead>
<tr>
<th>Study 52:</th>
<th>Safety and Efficacy of Combination Saxagliptin &amp; Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01606007" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01606007" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 53:</td>
<td>Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01342484" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01342484" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 54:</td>
<td>BMS-Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01498185" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01498185" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 55:</td>
<td>Pharmacokinetics, Pharmacodynamics and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT00957268" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT00957268" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 56:</td>
<td>A Phase III Study to Evaluate Safety, Tolerability and Efficacy of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01421966" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01421966" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 57:</td>
<td>Phase 2 Study to Evaluate Safety &amp; Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01571297" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01571297" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 58:</td>
<td>A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01487109" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01487109" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 59:</td>
<td>A Pharmacodynamic/Pharmacokinetic Study of Alogliptin in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01398267" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01398267" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 60:</td>
<td>Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01549769" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01549769" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 61:</td>
<td>Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01452451" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01452451" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 62:</td>
<td>Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01555008" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01555008" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 63:</td>
<td>Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01676220" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01676220" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 64:</td>
<td>A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01686620" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01686620" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 65:</td>
<td>Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of Glymera Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01658501" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01658501" alt="ClinicalTrials.gov" /></td>
</tr>
<tr>
<td>Study 66:</td>
<td>A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone</td>
</tr>
<tr>
<td><img src="http://ClinicalTrials.gov/show/NCT01691846" alt="ClinicalTrials.gov" /></td>
<td><img src="http://ClinicalTrials.gov/show/NCT01691846" alt="ClinicalTrials.gov" /></td>
</tr>
</tbody>
</table>
**Study 67:**
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy
http://ClinicalTrials.gov/show/NCT01691989

**Study 68:**
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
http://ClinicalTrials.gov/show/NCT01200394

**Study 69:**
Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
http://ClinicalTrials.gov/show/NCT01549964

**Study 70:**
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
http://ClinicalTrials.gov/show/NCT01308437

**Study 71:**
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
http://ClinicalTrials.gov/show/NCT01497938

**Study 72:**
Effects of Metreleptin in Type 1 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01268644

**Study 73:**
Insulin Resistance Intervention After Stroke Trial
http://ClinicalTrials.gov/show/NCT00091949

**Study 74:**
A Study in Patients With Diabetic Kidney Disease
http://ClinicalTrials.gov/show/NCT01113801

**Study 75:**
Novel Therapies for Metabolic Complications of Lipodystrophies
http://ClinicalTrials.gov/show/NCT00457938

**Study 76:**
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
http://ClinicalTrials.gov/show/NCT01496365

**Study 77:**
Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers
http://ClinicalTrials.gov/show/NCT00926068

**Study 78:**
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
http://ClinicalTrials.gov/show/NCT01147250

**Study 79:**
Efficacy and Safety Trial of Intravitreal Injections Combined With PRP for the Treatment of CSME Secondary to Diabetes Mellitus (DAVE)
http://ClinicalTrials.gov/show/NCT01552408

**Study 80:**
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
http://ClinicalTrials.gov/show/NCT01683409

**Study 81:**
A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
http://ClinicalTrials.gov/show/NCT01533428

**Study 82:**
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
http://ClinicalTrials.gov/show/NCT01601236

**Study 83:**
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021 AM1)
http://ClinicalTrials.gov/show/NCT01564459
**Study 84:**
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
http://ClinicalTrials.gov/show/NCT01455415

**Study 85:**
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
http://ClinicalTrials.gov/show/NCT01474772

**Study 86:**
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
http://ClinicalTrials.gov/show/NCT01445899

**Study 87:**
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers
http://ClinicalTrials.gov/show/NCT01070433

**Study 88:**
Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
http://ClinicalTrials.gov/show/NCT01291160

**Study 89:**
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
http://ClinicalTrials.gov/show/NCT01475786

**Study 90:**
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
http://ClinicalTrials.gov/show/NCT01489189

**Study 91:**
Cardiovascular Outcomes Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
http://ClinicalTrials.gov/show/NCT01601704

**Study 92:**
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
http://ClinicalTrials.gov/show/NCT01262898

**Heart Disease (49 clinical trials recruiting)**

**Study 1:**
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
http://ClinicalTrials.gov/show/NCT01609140

**Study 2:**
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
http://ClinicalTrials.gov/show/NCT01516541

**Study 3:**
Intracardiac Cryoablation for AtrioVentricular Nodal Reentrant Tachycardia
http://ClinicalTrials.gov/show/NCT01426425

**Study 4:**
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/ Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillators (ICD) (SHIELD-2)
http://ClinicalTrials.gov/show/NCT01464476

**Study 5:**
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
http://ClinicalTrials.gov/show/NCT01508910

**Study 6:**
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
http://ClinicalTrials.gov/show/NCT01042769
Study 7:
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia
http://ClinicalTrials.gov/show/NCT01556022

Study 8:
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)
http://ClinicalTrials.gov/show/NCT00683696

Study 9:
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
http://ClinicalTrials.gov/show/NCT01225562

Study 10:
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
http://ClinicalTrials.gov/show/NCT01531374

Study 11:
A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
http://ClinicalTrials.gov/show/NCT01643330

Study 12:
RED-HF™ Trial-Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
http://ClinicalTrials.gov/show/NCT00358215

Study 13:
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
http://ClinicalTrials.gov/show/NCT01347710

Study 14:
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
http://ClinicalTrials.gov/show/NCT01442038

Study 15:
Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions
http://ClinicalTrials.gov/show/NCT01092416

Study 16:
ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients
http://ClinicalTrials.gov/show/NCT01424722

Study 17:
Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure
http://ClinicalTrials.gov/show/NCT01251406

Study 18:
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome
http://ClinicalTrials.gov/show/NCT00968708

Study 19:
AngelMed for Early Recognition and Treatment of STEMI
http://ClinicalTrials.gov/show/NCT00781118

Study 20:
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
http://ClinicalTrials.gov/show/NCT01147250

Study 21:
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
http://ClinicalTrials.gov/show/NCT01076764

Study 22:
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
http://ClinicalTrials.gov/show/NCT01327846
Study 23:
The PARTNER II Trial: Placement of AoRTic TraNsclatEther Valves
http://ClinicalTrials.gov/show/NCT01314313

Study 24:
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction
http://ClinicalTrials.gov/show/NCT01495364

Study 25:
Vest Prevention of Early Sudden Death Trial and VEST Registry
http://ClinicalTrials.gov/show/NCT01446965

Study 26:
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System-Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)
http://ClinicalTrials.gov/show/NCT01456000

Study 27:
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)
http://ClinicalTrials.gov/show/NCT01522651

Study 28:
Efficacy of LCQ908 on Cardiovascular Risk
http://ClinicalTrials.gov/show/NCT01474434

Study 29:
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
http://ClinicalTrials.gov/show/NCT01618669

Study 30:
Feasibility Study of BMAC Enhanced CABG
http://ClinicalTrials.gov/show/NCT01074099

Study 31:
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
http://ClinicalTrials.gov/show/NCT01300013

Study 32:
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
http://ClinicalTrials.gov/show/NCT01268319

Study 33:
Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
http://ClinicalTrials.gov/show/NCT00555828

Study 34:
Clinical Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients
http://ClinicalTrials.gov/show/NCT01626079

Study 35:
Premium Migraine Trial
http://ClinicalTrials.gov/show/NCT00355056

Study 36:
Post-Myocardial Infarction Remodeling Prevention Therapy
http://ClinicalTrials.gov/show/NCT01213251

Study 37:
INcrease Of VAgal TonE in CHF
http://ClinicalTrials.gov/show/NCT01303718

Study 38:
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
http://ClinicalTrials.gov/show/NCT01670981
**Study 39:**
Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair
http://ClinicalTrials.gov/show/NCT00567853

**Study 40:**
Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study
http://ClinicalTrials.gov/show/NCT01656772

**Study 41:**
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
http://ClinicalTrials.gov/show/NCT01483183

**Study 42:**
THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS
http://ClinicalTrials.gov/show/NCT01639495

**Study 43:**
Insulin Resistance Intervention After Stroke Trial
http://ClinicalTrials.gov/show/NCT00091949

**Study 44:**
Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia
http://ClinicalTrials.gov/show/NCT01401647

**Study 45:**
Clarification of Optimal Anticoagulation Through Genetics
http://ClinicalTrials.gov/show/NCT00839657

**Study 46:**
Cardiovascular Outcomes Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
http://ClinicalTrials.gov/show/NCT01601704

**Study 47:**
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects
http://ClinicalTrials.gov/show/NCT01602328

**Study 48:**
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
http://ClinicalTrials.gov/show/NCT00886743

**Study 49:**
Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities
http://ClinicalTrials.gov/show/NCT01101035

**Mental Illness**
(96 clinical trials recruiting)

**Study 1:**
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
http://ClinicalTrials.gov/show/NCT01360632

**Study 2:**
Progressive Goal Attainment Program for Veterans
http://ClinicalTrials.gov/show/NCT01565863

**Study 3:**
SPDS03 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
http://ClinicalTrials.gov/show/NCT01470469

**Study 4:**
Relapse Prevention Study in Patients With Schizophrenia
http://ClinicalTrials.gov/show/NCT01291511
Study 5:
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
http://ClinicalTrials.gov/show/NCT01485965

Study 6:
Dose-optimization in Adolescents Aged 13–17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
http://ClinicalTrials.gov/show/NCT01081132

Study 7:
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
http://ClinicalTrials.gov/show/NCT01592786

Study 8:
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
http://ClinicalTrials.gov/show/NCT01338818

Study 9:
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
http://ClinicalTrials.gov/show/NCT01405053

Study 10:
A Trial of CM-AT in Children With Autism- Open Label Extension Study
http://ClinicalTrials.gov/show/NCT00912691

Study 11:
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
http://ClinicalTrials.gov/show/NCT01122927

Study 12:
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson’s Disease Psychosis
http://ClinicalTrials.gov/show/NCT00550238

Study 13:
Treatment of Sleep Problems in Children With Autism Spectrum Disorder With Melatonin
http://ClinicalTrials.gov/show/NCT00691080

Study 14:
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
http://ClinicalTrials.gov/show/NCT01396447

Study 15:
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01469377

Study 16:
Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia
http://ClinicalTrials.gov/show/NCT01412060

Study 17:
Extension Study of Asenapine (P06107 (NCT01244815)) for Pediatric Bipolar Disorder (P05898 AM3)
http://ClinicalTrials.gov/show/NCT01349907

Study 18:
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension (P05898; NCT01349907)(P06107 AM3)
http://ClinicalTrials.gov/show/NCT01244815

Study 19:
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
http://ClinicalTrials.gov/show/NCT01432444
**Study 21:**
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
http://ClinicalTrials.gov/show/NCT01361555

**Study 22:**
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
http://ClinicalTrials.gov/show/NCT01369095

**Study 23:**
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
http://ClinicalTrials.gov/show/NCT01371708

**Study 24:**
PEARL Schizophrenia Maintenance
http://ClinicalTrials.gov/show/NCT01435928

**Study 25:**
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
http://ClinicalTrials.gov/show/NCT01371734

**Study 26:**
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
http://ClinicalTrials.gov/show/NCT01121536

**Study 27:**
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01435759

**Study 28:**
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
http://ClinicalTrials.gov/show/NCT01467700

**Study 29:**
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
http://ClinicalTrials.gov/show/NCT01500200

**Study 30:**
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01173601

**Study 31:**
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients
http://ClinicalTrials.gov/show/NCT01467713

**Study 32:**
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
http://ClinicalTrials.gov/show/NCT01529515

**Study 33:**
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
http://ClinicalTrials.gov/show/NCT01235520

**Study 34:**
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
http://ClinicalTrials.gov/show/NCT01072630

**Study 35:**
Major Depressive Disorder (MDD) With Mixed Features-Flexible Dose
http://ClinicalTrials.gov/show/NCT01421134

**Study 36:**
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
http://ClinicalTrials.gov/show/NCT01309945
<table>
<thead>
<tr>
<th>Study 37:</th>
<th>Study 46:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Depressive Disorder With Mixed Features-Extension</td>
<td>Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01423253">http://ClinicalTrials.gov/show/NCT01423253</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01393613">http://ClinicalTrials.gov/show/NCT01393613</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 38:</th>
<th>Study 47:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Twelve Week, Open Label Extension Study in Patients With Schizophrenia</td>
<td>Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01566162">http://ClinicalTrials.gov/show/NCT01566162</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01488929">http://ClinicalTrials.gov/show/NCT01488929</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 39:</th>
<th>Study 48:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder</td>
<td>A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01564862">http://ClinicalTrials.gov/show/NCT01564862</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01432236">http://ClinicalTrials.gov/show/NCT01432236</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 40:</th>
<th>Study 49:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)</td>
<td>A Study to Evaluate the Efficacy and Safety of ALKS 9072 in Subjects With Schizophrenia</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01521663">http://ClinicalTrials.gov/show/NCT01521663</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01469039">http://ClinicalTrials.gov/show/NCT01469039</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 41:</th>
<th>Study 50:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)</td>
<td>Major Depressive Disorder With Mixed Features</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01192867">http://ClinicalTrials.gov/show/NCT01192867</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01423240">http://ClinicalTrials.gov/show/NCT01423240</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 42:</th>
<th>Study 51:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia</td>
<td>Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01655680">http://ClinicalTrials.gov/show/NCT01655680</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01436162">http://ClinicalTrials.gov/show/NCT01436162</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 43:</th>
<th>Study 52:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia</td>
<td>A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01397786">http://ClinicalTrials.gov/show/NCT01397786</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01192880">http://ClinicalTrials.gov/show/NCT01192880</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 44:</th>
<th>Study 53:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 3 IGIV, 10% in Alzheimer’s Disease</td>
<td>A Study of Gantenerumab in Patients With Prodromal Alzheimer’s Disease</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01524887">http://ClinicalTrials.gov/show/NCT01524887</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01224106">http://ClinicalTrials.gov/show/NCT01224106</a></td>
</tr>
</tbody>
</table>

| Study 45: |  |
|----------|  |
| Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder |  |
| http://ClinicalTrials.gov/show/NCT01305408 |  |
**Study 54:**
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor (SSRI)
http://ClinicalTrials.gov/show/NCT01361815

**Study 55:**
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01482221

**Study 56:**
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
http://ClinicalTrials.gov/show/NCT01681121

**Study 57:**
Efficacy and Safety of Tasmelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
http://ClinicalTrials.gov/show/NCT01163032

**Study 58:**
Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01364649

**Study 59:**
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
http://ClinicalTrials.gov/show/NCT01430754

**Study 60:**
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
http://ClinicalTrials.gov/show/NCT01626456

**Study 61:**
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
http://ClinicalTrials.gov/show/NCT01235559

**Study 62:**
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
http://ClinicalTrials.gov/show/NCT01569464

**Study 63:**
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
http://ClinicalTrials.gov/show/NCT01518374

**Study 64:**
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM2)
http://ClinicalTrials.gov/show/NCT01554176

**Study 65:**
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
http://ClinicalTrials.gov/show/NCT01457677

**Study 66:**
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
http://ClinicalTrials.gov/show/NCT01234779

**Study 67:**
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression
http://ClinicalTrials.gov/show/NCT01566591

**Study 68:**
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
http://ClinicalTrials.gov/show/NCT01318434

**Study 69:**
VI-1121 for the Treatment Alzheimer’s Disease
http://ClinicalTrials.gov/show/NCT01428362
**Study 70:**
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
http://ClinicalTrials.gov/show/NCT01192906

**Study 71:**
A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
http://ClinicalTrials.gov/show/NCT01187407

**Study 72:**
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
http://ClinicalTrials.gov/show/NCT01072812

**Study 73:**
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
http://ClinicalTrials.gov/show/NCT01429116

**Study 74:**
20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
http://ClinicalTrials.gov/show/NCT01568216

**Study 75:**
Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome
http://ClinicalTrials.gov/show/NCT01498120

**Study 76:**
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
http://ClinicalTrials.gov/show/NCT01371721

**Study 77:**
Study of the Effectiveness of Three Different Doses of OPG-34712 in the Treatment of Adults With Acute Schizophrenia
http://ClinicalTrials.gov/show/NCT01396421

**Study 78:**
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
http://ClinicalTrials.gov/show/NCT01493726

**Study 79:**
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
http://ClinicalTrials.gov/show/NCT01568229

**Study 80:**
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01370733

**Study 81:**
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
http://ClinicalTrials.gov/show/NCT01688037

**Study 82:**
The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome
http://ClinicalTrials.gov/show/NCT01569438

**Study 83:**
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
http://ClinicalTrials.gov/show/NCT01537042

**Study 84:**
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
http://ClinicalTrials.gov/show/NCT01436149
<table>
<thead>
<tr>
<th>Study 85:</th>
<th>Study 86:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Study Of DVS SR In Treatment Of Children And</td>
<td>Efficacy &amp; Safety Study of Oral Aripiprazole</td>
</tr>
<tr>
<td>Adolescent Outpatients With MDD</td>
<td>in Adolescents With Schizophrenia</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01372150">http://ClinicalTrials.gov/show/NCT01372150</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01149655">http://ClinicalTrials.gov/show/NCT01149655</a></td>
</tr>
<tr>
<td>Study 87:</td>
<td>Study 88:</td>
</tr>
<tr>
<td>A Study to Evaluate the Efficacy and Safety of</td>
<td>Safety, Efficacy and Tolerability of Vilazodone</td>
</tr>
<tr>
<td>MABT5102A in Patients With Mild to Moderate</td>
<td>in Generalized Anxiety Disorder</td>
</tr>
<tr>
<td>Alzheimer's Disease (ABBY)</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01343966">http://ClinicalTrials.gov/show/NCT01343966</a></td>
</tr>
<tr>
<td>Study 89:</td>
<td>Study 90:</td>
</tr>
<tr>
<td>A Study in Prevention of Re-emergence of</td>
<td>Study to Evaluate the Pharmacokinetics,</td>
</tr>
<tr>
<td>Depression Symptoms</td>
<td>Pharmacodynamics, and Safety of Armodafinil</td>
</tr>
<tr>
<td></td>
<td>in Children and Adolescents With Excessive</td>
</tr>
<tr>
<td></td>
<td>Sleepiness Associated With Narcolepsy</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01299272">http://ClinicalTrials.gov/show/NCT01299272</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01624480">http://ClinicalTrials.gov/show/NCT01624480</a></td>
</tr>
<tr>
<td>Study 91:</td>
<td>Study 92:</td>
</tr>
<tr>
<td>A Study to Evaluate the Effect of Genotype on</td>
<td>A Study of RO4917838 (Bitopertin) in Patients</td>
</tr>
<tr>
<td>LY2216684</td>
<td>With Sub-optimally Controlled Symptoms of</td>
</tr>
<tr>
<td></td>
<td>Schizophrenia (WN25306)</td>
</tr>
<tr>
<td></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01460381">http://ClinicalTrials.gov/show/NCT01460381</a></td>
</tr>
<tr>
<td></td>
<td>Study 93:</td>
</tr>
<tr>
<td>Study 93:</td>
<td>Dose Escalating Study of Rotigotine in</td>
</tr>
<tr>
<td></td>
<td>Pediatric Subjects With Restless Legs</td>
</tr>
<tr>
<td></td>
<td>Syndrome</td>
</tr>
<tr>
<td>Study 94:</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01495793">http://ClinicalTrials.gov/show/NCT01495793</a></td>
</tr>
<tr>
<td>Study 95:</td>
<td>Study 96:</td>
</tr>
<tr>
<td>Preventing Sexual Dysfunction With Aromatase</td>
<td>Multisite Controlled Trial of Cocaine Vaccine</td>
</tr>
<tr>
<td>Inhibitors</td>
<td><a href="http://ClinicalTrials.gov/show/NCT01603303">http://ClinicalTrials.gov/show/NCT01603303</a></td>
</tr>
<tr>
<td></td>
<td>Study 97:</td>
</tr>
<tr>
<td>Stroke</td>
<td>Safety, Efficacy and Tolerability of Vilazodone</td>
</tr>
<tr>
<td>(15 clinical trials recruiting)</td>
<td>in Generalized Anxiety Disorder</td>
</tr>
<tr>
<td>Study 1:</td>
<td>Study 2:</td>
</tr>
<tr>
<td>Study of ALD-401 Via Intracarotid Infusion in</td>
<td>Efficacy and Safety Study of Desmoteplase to</td>
</tr>
<tr>
<td>Ischemic Stroke Subjects</td>
<td>Treat Acute Ischemic Stroke (DIAS-4)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT01273337">http://ClinicalTrials.gov/show/NCT01273337</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT00856661">http://ClinicalTrials.gov/show/NCT00856661</a></td>
</tr>
<tr>
<td>Study 3:</td>
<td>Study 4:</td>
</tr>
<tr>
<td>Carotid Stenting vs. Surgery of Severe Carotid</td>
<td>Efficacy and Safety Trial of Transcranial</td>
</tr>
<tr>
<td>Artery Disease and Stroke Prevention in</td>
<td>Laser Therapy Within 24 Hours From Stroke</td>
</tr>
<tr>
<td>Asymptomatic Patients (ACT I)</td>
<td>Onset (NEST-3)</td>
</tr>
<tr>
<td><a href="http://ClinicalTrials.gov/show/NCT00106938">http://ClinicalTrials.gov/show/NCT00106938</a></td>
<td><a href="http://ClinicalTrials.gov/show/NCT01120301">http://ClinicalTrials.gov/show/NCT01120301</a></td>
</tr>
</tbody>
</table>
**Study 5:**

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

http://ClinicalTrials.gov/show/NCT01225562

**Study 6:**

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

http://ClinicalTrials.gov/show/NCT01392300

**Study 7:**

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

http://ClinicalTrials.gov/show/NCT01464307

**Study 8:**

Insulin Resistance Intervention After Stroke Trial

http://ClinicalTrials.gov/show/NCT00091949

**Study 9:**

Safety of Intravenous Thrombolysis for Wake-up Stroke

http://ClinicalTrials.gov/show/NCT01183533

**Study 10:**

Clarification of Optimal Anticoagulation Through Genetics

http://ClinicalTrials.gov/show/NCT00839657

**Study 11:**

Dysport® Adult Lower Limb Spasticity Study

http://ClinicalTrials.gov/show/NCT01249404

**Study 12:**

Dysport® Adult Upper Limb Spasticity

http://ClinicalTrials.gov/show/NCT01313299

**Study 13:**

Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

http://ClinicalTrials.gov/show/NCT00968708

**Study 14:**

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

http://ClinicalTrials.gov/show/NCT01101035

**Study 15:**

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

http://ClinicalTrials.gov/show/NCT01327846